Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bacterial Infections and Mycoses

  Free Subscription


Articles published in J Antimicrob Chemother

Retrieve available abstracts of 421 articles:
HTML format



Single Articles


    March 2024
  1. TESSIER E, Ruffier d'Epenoux L, Lartigue MF, Chaufour L, et al
    Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: a CRIOGO multicentre retrospective study.
    J Antimicrob Chemother. 2024 Mar 20:dkae071. doi: 10.1093.
    PubMed     Abstract available


  2. PHILIP A, Oueslati S, Villa F, Pannetier C, et al
    Development of an ultrafast PCR to detect clinically relevant acquired vancomycin-resistance genes from cultured enterococci.
    J Antimicrob Chemother. 2024 Mar 19:dkae062. doi: 10.1093.
    PubMed     Abstract available


  3. YUNIVITA V, Gafar F, Santoso P, Chaidir L, et al
    Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.
    J Antimicrob Chemother. 2024 Mar 9:dkae057. doi: 10.1093.
    PubMed     Abstract available


  4. ANJUM MF, Duggett N, Sheldon E, Sharma M, et al
    Genomics to detect transmission of livestock-associated methicillin-resistant Staphylococcus aureus from UK pigs in abattoirs during slaughter.
    J Antimicrob Chemother. 2024 Mar 5:dkae052. doi: 10.1093.
    PubMed     Abstract available


  5. CHEN RZ, Lu PL, Yang TY, Lin SY, et al
    Efficacy of cefoperazone/sulbactam for ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and the factors associated with poor outcomes.
    J Antimicrob Chemother. 2024;79:648-655.
    PubMed     Abstract available


  6. MOREELS N, Boven A, Gressani O, Andersson FL, et al
    The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence.
    J Antimicrob Chemother. 2024;79:608-616.
    PubMed     Abstract available


  7. SELBY PR, Heffernan AJ, Yeung D, Warner MS, et al
    Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients.
    J Antimicrob Chemother. 2024;79:567-577.
    PubMed     Abstract available


    February 2024
  8. VAN HAL SJ, Jensen SO, Tong SYC, Bentley S, et al
    Unravelling the complex interplay between antibiotic consumption and adaptive changes in methicillin-resistant Staphylococcus aureus.
    J Antimicrob Chemother. 2024 Feb 27:dkae048. doi: 10.1093.
    PubMed     Abstract available


  9. FANG ZY, Zhang ZY, Zheng YD, Lei D, et al
    Repurposing cinacalcet suppresses multidrug-resistant Staphylococcus aureus by disruption of cell membrane and inhibits biofilm by targeting IcaR.
    J Antimicrob Chemother. 2024 Feb 27:dkae051. doi: 10.1093.
    PubMed     Abstract available


  10. COTRONEO N, Stokes SS, Pucci MJ, Rubio A, et al
    Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection.
    J Antimicrob Chemother. 2024 Feb 23:dkae046. doi: 10.1093.
    PubMed     Abstract available


  11. BRENCIANI A, Cinthi M, Coccitto SN, Massacci FR, et al
    Global spread of the linezolid-resistant Enterococcus faecalis ST476 clonal lineage carrying optrA.
    J Antimicrob Chemother. 2024 Feb 15:dkae039. doi: 10.1093.
    PubMed     Abstract available


  12. WESTBROOK KJ, Chilambi GS, Stellfox ME, Nordstrom HR, et al
    Differential in vitro susceptibility to ampicillin/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates.
    J Antimicrob Chemother. 2024 Feb 9:dkae032. doi: 10.1093.
    PubMed     Abstract available


  13. ATAMNA A, Yeshurun M, Shargian L, Raanani P, et al
    Fatal invasive pulmonary and cerebral aspergillosis due to triazole-resistant Aspergillus fumigatus with multiple CYP51A mutations.
    J Antimicrob Chemother. 2024 Feb 9:dkae038. doi: 10.1093.
    PubMed    


  14. HELBO T, Boel JB, Bartels MD, Ahlstrom MG, et al
    Carriage of methicillin-resistant Staphylococcus aureus in children <6 years old: a retrospective follow-up study of the natural course and effectiveness of decolonization treatment.
    J Antimicrob Chemother. 2024 Feb 9:dkae036. doi: 10.1093.
    PubMed     Abstract available


  15. MCHUGH MP, Pettigrew KA, Taori S, Evans TJ, et al
    Consideration of within-patient diversity highlights transmission pathways and antimicrobial resistance gene variability in vancomycin-resistant Enterococcus faecium.
    J Antimicrob Chemother. 2024 Feb 7:dkae023. doi: 10.1093.
    PubMed     Abstract available


  16. LAITILA T, Sankilampi U, Renko M, Kokki M, et al
    Comment on: Identifying a therapeutic target for vancomycin against staphylococci in young infants.
    J Antimicrob Chemother. 2024 Feb 2:dkae014. doi: 10.1093.
    PubMed    


  17. VAN OS W, Zeitlinger M
    Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections.
    J Antimicrob Chemother. 2024;79:443-446.
    PubMed     Abstract available


  18. RANDO E, Salvati F, Sangiorgi F, Catania F, et al
    Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort s
    J Antimicrob Chemother. 2024;79:453-461.
    PubMed     Abstract available


  19. BLOOMFIELD M, van der Werff K, Todd S, Balm M, et al
    Effect of directive laboratory comments on prescribing response to positive throat swab cultures.
    J Antimicrob Chemother. 2024;79:334-338.
    PubMed     Abstract available


  20. KON H, Lurie-Weinberger MN, Lugassy C, Chen D, et al
    Use of Fourier-transform infrared spectroscopy for real-time outbreak investigation of OXA-48-producing Escherichia coli.
    J Antimicrob Chemother. 2024;79:349-353.
    PubMed     Abstract available


  21. HOSAKA Y, Muraki Y, Kajihara T, Kawakami S, et al
    Antimicrobial use and combination of resistance phenotypes in bacteraemic Escherichia coli in primary care: a study based on Japanese national data in 2018.
    J Antimicrob Chemother. 2024;79:312-319.
    PubMed     Abstract available


  22. MATSUO T, Wurster S, Jiang Y, Sasaki K, et al
    Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes.
    J Antimicrob Chemother. 2024;79:297-306.
    PubMed     Abstract available


    January 2024
  23. SACRAMENTO AG, Sartori L, Fontana H, Fuga B, et al
    Healthcare-associated vanA-positive Enterococcus faecium clone ST612 emerging as pathogen of companion animals in Brazil.
    J Antimicrob Chemother. 2024 Jan 25:dkae010. doi: 10.1093.
    PubMed    


  24. MAZZITELLI M, Scaglione V, Cattarin L, Franchin E, et al
    Off-label oritavancin treatment outcome and molecular characterization of a vancomycin- and linezolid-resistant Enterococcus faecium causing liver abscesses.
    J Antimicrob Chemother. 2024 Jan 16:dkad410. doi: 10.1093.
    PubMed    


  25. FLEITAS O, Fontes W, De Souza CM, Da Costa MC, et al
    A proteomic perspective on the resistance response of Klebsiella pneumoniae to antimicrobial peptide PaDBS1R1.
    J Antimicrob Chemother. 2024;79:112-122.
    PubMed     Abstract available


  26. RITCHIE G, Chorlton SD, Matic N, Bilawka J, et al
    WGS of a cluster of MDR Shigella sonnei utilizing Oxford Nanopore R10.4.1 long-read sequencing.
    J Antimicrob Chemother. 2024;79:55-60.
    PubMed     Abstract available


  27. SINGH S, Boorgula GD, Aryal S, Philley JV, et al
    Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so far.
    J Antimicrob Chemother. 2024;79:96-99.
    PubMed     Abstract available


  28. TAN MC, Huang YC, Chen PJ, Huang WC, et al
    In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species.
    J Antimicrob Chemother. 2024;79:200-202.
    PubMed    


    December 2023
  29. MASSACCI FR, Cucco L, Paniccia M, Luppi A, et al
    Streptococcus suis serotype 9 in Italy: genomic insights into high-risk clones with emerging resistance to penicillin.
    J Antimicrob Chemother. 2023 Dec 28:dkad395. doi: 10.1093.
    PubMed     Abstract available


  30. XU C, Li Y, Li Y, Huang L, et al
    Characterization of an ST38 carbapenem-resistant and highly virulent Escherichia coli carrying conjugatively transferable ColV virulence-resistance and blaNDM-5-positive resistance plasmids.
    J Antimicrob Chemother. 2023 Dec 28:dkad403. doi: 10.1093.
    PubMed     Abstract available


  31. OMAR S, Whitfield MG, Nolan MB, Ngom JT, et al
    Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.
    J Antimicrob Chemother. 2023 Dec 22:dkad372. doi: 10.1093.
    PubMed     Abstract available


  32. MANTZOURANI E, Ahmed H, Evans A, Gunnarsson R, et al
    A pharmacy-led sore throat test and treat (STTT) service: antigen testing and antibiotic supply rates during the period of heightened public awareness of Group A Streptococcus infections.
    J Antimicrob Chemother. 2023 Dec 22:dkad388. doi: 10.1093.
    PubMed     Abstract available


  33. ZHAO M, He S, Wen R, Li C, et al
    Membrane vesicles derived from Enterococcus faecalis promote the co-transfer of important antibiotic resistance genes located on both plasmids and chromosomes.
    J Antimicrob Chemother. 2023 Dec 18:dkad381. doi: 10.1093.
    PubMed     Abstract available


  34. COMBRINCK J, Tshavhungwe P, Rohlwink U, Enslin N, et al
    Rifampicin and protein concentrations in paired spinal versus ventricular cerebrospinal fluid samples of children with tuberculous meningitis.
    J Antimicrob Chemother. 2023 Dec 15:dkad371. doi: 10.1093.
    PubMed     Abstract available


  35. ERTL NG, Anderson TK, Pardo CJ, Maidment TI, et al
    Concurrent parC and gyrA fluoroquinolone resistance mutations and associated strains in Mycoplasma genitalium in Queensland, Australia.
    J Antimicrob Chemother. 2023 Dec 15:dkad373. doi: 10.1093.
    PubMed    


  36. BUIS DTP, van der Vaart TW, Prins JM, van der Meer JTM, et al
    Correction to: Comparative effectiveness of beta-lactams for empirical treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective cohort study.
    J Antimicrob Chemother. 2023 Dec 11:dkad385. doi: 10.1093.
    PubMed    


  37. DONA V, Nordmann P, Kittl S, Schuller S, et al
    Emergence of OXA-48-producing Enterobacter hormaechei in a Swiss companion animal clinic and their genetic relationship to clinical human isolates.
    J Antimicrob Chemother. 2023;78:2950-2960.
    PubMed     Abstract available


  38. SHENG Q, Wang N, Zhou Y, Deng X, et al
    A new function of thymol nanoemulsion for reversing colistin resistance in Salmonella enterica serovar Typhimurium infection.
    J Antimicrob Chemother. 2023;78:2983-2994.
    PubMed     Abstract available


  39. WANG X, Qin J, Xiang G, Wang C, et al
    Nosocomial dissemination of blaIMP-4 among Klebsiella pneumoniae by horizontal gene transfer and clonal spread: the epidemic IncN plasmids and the emerging high-risk IMP-4-producing ST101 clone.
    J Antimicrob Chemother. 2023;78:2890-2894.
    PubMed     Abstract available


  40. HERVOCHON C, Hennart B, Leroy AG, Corvec S, et al
    Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
    J Antimicrob Chemother. 2023;78:2919-2925.
    PubMed     Abstract available


  41. HAMON A, Benaboud S, Anjou M, Thoreau B, et al
    Dalbavancin: a new option for systemic treatment of Gram-positive endogenous endophthalmitis?
    J Antimicrob Chemother. 2023;78:3005-3006.
    PubMed    


  42. CORCIONE S, Vita D, De Nicolo A, Scabini S, et al
    Pharmacokinetics and pharmacogenetics of high-dosage tedizolid for disseminated nocardiosis in a lung transplant patient.
    J Antimicrob Chemother. 2023;78:3003-3004.
    PubMed    


    November 2023
  43. JIANG N, Chen H, Cheng L, Fu Q, et al
    Genomic analysis reveals the population structure and antimicrobial resistance of avian Pasteurella multocida in China.
    J Antimicrob Chemother. 2023 Nov 29:dkad365. doi: 10.1093.
    PubMed     Abstract available


  44. BEREDAKI MI, Pournaras S, Meletiadis J
    A new PK/PD target for assessing efficacy of micafungin against Candida parapsilosis.
    J Antimicrob Chemother. 2023 Nov 24:dkad360. doi: 10.1093.
    PubMed     Abstract available


  45. LEFRANC M, Accoceberry I, Fitton-Ouhabi V, Biteau N, et al
    Rapamycin and caspofungin show synergistic antifungal effects in caspofungin-susceptible and caspofungin-resistant Candida strains in vitro.
    J Antimicrob Chemother. 2023 Nov 22:dkad359. doi: 10.1093.
    PubMed     Abstract available


  46. NING YT, Sun TS, Dai RC, Luo ZY, et al
    Emergence of multiple fluconazole-resistant Candida parapsilosis sensu stricto clones with persistence and transmission in China.
    J Antimicrob Chemother. 2023 Nov 22:dkad356. doi: 10.1093.
    PubMed     Abstract available


  47. DAI X, Sun J, Zhao W, Wang J, et al
    Emergence of a novel ISS1N-optrA-carrying transposon within an integrative and conjugative element from Streptococcus parasuis.
    J Antimicrob Chemother. 2023 Nov 15:dkad347. doi: 10.1093.
    PubMed     Abstract available


  48. BOGLIONE-KERRIEN C, Zerrouki S, Le Bot A, Camus C, et al
    Can we predict the influence of inflammation on voriconazole exposure? An overview.
    J Antimicrob Chemother. 2023;78:2630-2636.
    PubMed     Abstract available


  49. KANESAKA I, Ohno A, Morita M, Katsuse AK, et al
    Epigenetic effects of ceftriaxone-resistant Neisseria gonorrhoeae FC428 mosaic-like sequences found in PenA sequences unique to Neisseria subflava and related species.
    J Antimicrob Chemother. 2023;78:2683-2690.
    PubMed     Abstract available


  50. WANG J, Jiang Y, Tian YQ, Qin YY, et al
    Detection of cfr in Klebsiella pneumoniae from pig feed in China.
    J Antimicrob Chemother. 2023;78:2774-2776.
    PubMed    


    October 2023
  51. DUBERT M, Kably B, Derobertmasure A, Podglajen I, et al
    Evaluating the heart valve tissue diffusion of amoxicillin in infective endocarditis: a pilot prospective observational non-comparative study.
    J Antimicrob Chemother. 2023 Oct 25:dkad330. doi: 10.1093.
    PubMed     Abstract available


  52. CALADO NOGUEIRA DE MOURA V, Nguyen MH, Hunkins JJ, Daley CL, et al
    In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022.
    J Antimicrob Chemother. 2023 Oct 21:dkad317. doi: 10.1093.
    PubMed     Abstract available


  53. TRUSWELL A, Lee ZZ, Stegger M, Blinco J, et al
    Augmented surveillance of antimicrobial resistance with high-throughput robotics detects transnational flow of fluoroquinolone-resistant Escherichia coli strain into poultry.
    J Antimicrob Chemother. 2023 Oct 21:dkad323. doi: 10.1093.
    PubMed     Abstract available


  54. CINTHI M, Coccitto SN, Simoni S, Zeni G, et al
    Characterization of a non-functional erm(T) gene in a clinical Enterococcus faecium strain.
    J Antimicrob Chemother. 2023 Oct 14:dkad321. doi: 10.1093.
    PubMed    


  55. BOCK M, Van Hasselt JGC, Schwartz F, Wang H, et al
    Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis.
    J Antimicrob Chemother. 2023 Oct 12:dkad316. doi: 10.1093.
    PubMed     Abstract available


  56. HALLIDAY C, Kim HY, Tay E, Chen SCA, et al
    Exploring synergy between azole antifungal drugs and statins for Candida auris.
    J Antimicrob Chemother. 2023 Oct 12:dkad303. doi: 10.1093.
    PubMed     Abstract available


  57. SIOPI M, Georgiou PC, Pournaras S, Meletiadis J, et al
    Optimization of the EUCAST reference broth microdilution method for echinocandin susceptibility testing of Aspergillus fumigatus.
    J Antimicrob Chemother. 2023 Oct 9:dkad306. doi: 10.1093.
    PubMed     Abstract available


  58. PICCICA M, Spinicci M, Botta A, Bianco V, et al
    Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience.
    J Antimicrob Chemother. 2023 Oct 9:dkad298. doi: 10.1093.
    PubMed     Abstract available


  59. TRAN A, Zureik M, Sibiude J, Drouin J, et al
    Prevalence and associated factors of antibiotic exposure during pregnancy in a large French population-based study during the 2010-19 period.
    J Antimicrob Chemother. 2023;78:2535-2543.
    PubMed     Abstract available


  60. GIACOBBE DR, Marelli C, Cattardico G, Fanelli C, et al
    Mortality in KPC-producing Klebsiella pneumoniae bloodstream infections: a changing landscape.
    J Antimicrob Chemother. 2023;78:2505-2514.
    PubMed     Abstract available


  61. PAPPAS PG, Vazquez JA, Oren I, Rahav G, et al
    Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.
    J Antimicrob Chemother. 2023;78:2471-2480.
    PubMed     Abstract available


  62. WANG J, Zhang XX, Jiang Y, Mei CY, et al
    Detection of blaNDM-1 in Moellerella wisconsensis from mutton, China.
    J Antimicrob Chemother. 2023;78:2599-2601.
    PubMed    


    September 2023
  63. MOK S, Roycroft E, Flanagan PR, Wagener J, et al
    Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
    J Antimicrob Chemother. 2023 Sep 23:dkad252. doi: 10.1093.
    PubMed     Abstract available


  64. AKERLUND A, Serrander L, Sundqvist M
    Short incubation of disc diffusion for Streptococcus pneumoniae and Haemophilus influenzae to reduce time to susceptibility report.
    J Antimicrob Chemother. 2023 Sep 5:dkad272. doi: 10.1093.
    PubMed     Abstract available


  65. ZHOU W, Jin Y, Shen P, Chen W, et al
    Novel SCCmec variants in clonal complex 398 and lineage-specific pseudo-SCCmec identified in ST88 MRSA from invasive bloodstream infections in China.
    J Antimicrob Chemother. 2023;78:2366-2375.
    PubMed     Abstract available


  66. BECERRA-APARICIO F, Gomez-Zorrilla S, Hernandez-Garcia M, Gijon D, et al
    Significant increase of CTX-M-15-ST131 and emergence of CTX-M-27-ST131 Escherichia coli high-risk clones causing healthcare-associated bacteraemia of urinary origin in Spain (ITUBRAS-2 project).
    J Antimicrob Chemother. 2023;78:2291-2296.
    PubMed     Abstract available


  67. ROHDE AM, Mischnik A, Behnke M, Dinkelacker A, et al
    Association of ward-level antibiotic consumption with healthcare-associated Clostridioides difficile infections: an ecological study in five German university hospitals, 2017-2019.
    J Antimicrob Chemother. 2023;78:2274-2282.
    PubMed     Abstract available


  68. ATTWOOD M, Griffin P, Noel AR, Albur M, et al
    Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic mod
    J Antimicrob Chemother. 2023;78:2254-2262.
    PubMed     Abstract available


  69. FRESAN D, Luque S, Sorli L, Grau S, et al
    Pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections-authors' response.
    J Antimicrob Chemother. 2023;78:2385-2386.
    PubMed    


  70. VAN HAL SJ, Whiley DM, Le T, Ray S, et al
    Rapid expansion of Neisseria gonorrhoeae ST7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype.
    J Antimicrob Chemother. 2023;78:2203-2208.
    PubMed     Abstract available


  71. BAVARO DF, Belati A, Diella L, Frallonardo L, et al
    Loading dose plus continuous/extended infusion versus intermittent bolus of beta-lactams for the treatment of Gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study.
    J Antimicrob Chemother. 2023;78:2175-2184.
    PubMed     Abstract available


  72. TISEO G, Suardi LR, Leonildi A, Giordano C, et al
    Meropenem/vaborbactam plus aztreonam for the treatment of New Delhi metallo-beta-lactamase-producing Klebsiella pneumoniae infections.
    J Antimicrob Chemother. 2023;78:2377-2379.
    PubMed    


    August 2023
  73. POWELL LM, Choi SJ, Haught BL, Demkowicz R, et al
    Prevalence of erythromycin-resistant emm92-type invasive group A streptococcal infections among injection drug users in West Virginia, United States, 2021-23.
    J Antimicrob Chemother. 2023 Aug 28:dkad268. doi: 10.1093.
    PubMed     Abstract available


  74. MOK HT, Teng CB, Bergin S, Hon PY, et al
    Treatment outcomes with benzylpenicillin and non-benzylpenicillin antibiotics, and the performance of the penicillin zone-edge test versus molecular detection of blaZ in penicillin-susceptible Staphylococcus aureus (PSSA) bacteraemia.
    J Antimicrob Chemother. 2023 Aug 19:dkad263. doi: 10.1093.
    PubMed     Abstract available


  75. GALARION LH, Trigwell J, Mohamad M, Nakamoto JA, et al
    The native ABC-F proteins of Staphylococcus aureus do not contribute to intrinsic resistance against ribosome-targeting antibacterial drugs.
    J Antimicrob Chemother. 2023 Aug 16:dkad238. doi: 10.1093.
    PubMed    


  76. DOTEL R, Gilbert GL, Hutabarat SN, Davis JS, et al
    Effectiveness of adjunctive rifampicin for treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis of randomized controlled trials.
    J Antimicrob Chemother. 2023 Aug 16:dkad214. doi: 10.1093.
    PubMed     Abstract available


  77. GREIG DR, Do Nascimento V, Olonade I, Swift C, et al
    Surveillance of antimicrobial resistant Shiga toxin-producing E. coli O157:H7 in England, 2016-2020.
    J Antimicrob Chemother. 2023 Aug 7:dkad231. doi: 10.1093.
    PubMed     Abstract available


  78. SKJOT-ARKIL H, Rune Nanthan K, Chen M, Rosenvinge FS, et al
    Carrier prevalence of Clostridioides difficile in emergency departments and the association of prior antibiotic consumption: a combined cross-sectional and nested case-control study.
    J Antimicrob Chemother. 2023;78:2089-2096.
    PubMed     Abstract available


  79. CARTER C, Hutchison A, Rudder S, Trotter E, et al
    Uropathogenic Escherichia coli population structure and antimicrobial susceptibility in Norfolk, UK.
    J Antimicrob Chemother. 2023;78:2028-2036.
    PubMed     Abstract available


  80. GAY N, Rabenandrasana MAN, Panandiniaina HP, Rakotoninidrina MF, et al
    One Health compartment analysis of ESBL-producing Escherichia coli reveals multiple transmission events in a rural area of Madagascar.
    J Antimicrob Chemother. 2023;78:1848-1858.
    PubMed     Abstract available


  81. DE LA VILLA S, Sanchez-Carrillo C, Sanchez-Martinez C, Cercenado E, et al
    Clinical impact of time to results from the microbiology laboratory in bloodstream infections caused by carbapenemase-producing Enterobacterales (TIME-CPE STUDY).
    J Antimicrob Chemother. 2023;78:1948-1954.
    PubMed     Abstract available


  82. STEMLER J, Mellinghoff SC, Khodamoradi Y, Sprute R, et al
    Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    J Antimicrob Chemother. 2023;78:1813-1826.
    PubMed     Abstract available


  83. SAATHOFF M, Tedin K, Gratz S, Schwerk P, et al
    Albicidin independency of multidrug efflux systems in Salmonella enterica serovar Typhimurium.
    J Antimicrob Chemother. 2023;78:2102-2104.
    PubMed    


  84. HERSHKO Y, Levytskyi K, Rannon E, Assous MV, et al
    Phenotypic and genotypic analysis of antimicrobial resistance in Nocardia species.
    J Antimicrob Chemother. 2023 Aug 1:dkad236. doi: 10.1093.
    PubMed     Abstract available


    July 2023
  85. ALAM F, Blackburn SA, Davis J, Massar K, et al
    Pseudomonas aeruginosa increases the susceptibility of Candida albicans to amphotericin B in dual-species biofilms.
    J Antimicrob Chemother. 2023 Jul 31:dkad228. doi: 10.1093.
    PubMed     Abstract available


  86. BENDER JK, Baufeld E, Becker K, Claus H, et al
    CHROMAgar LIN-R as an efficient screening tool to assess the prevalence of linezolid-resistant enterococci in German hospital patients-a multicentre study approach, 2021-2022.
    J Antimicrob Chemother. 2023 Jul 20:dkad218. doi: 10.1093.
    PubMed     Abstract available


  87. ASLAN AT, Tabah A, Koylu B, Kalem AK, et al
    Epidemiology and risk factors of 28-day mortality of hospital-acquired bloodstream infection in Turkish intensive care units: a prospective observational cohort study.
    J Antimicrob Chemother. 2023;78:1757-1768.
    PubMed     Abstract available


  88. GOLPARIAN D, Jacobsson S, Holley CL, Shafer WM, et al
    High-level in vitro resistance to gentamicin acquired in a stepwise manner in Neisseria gonorrhoeae.
    J Antimicrob Chemother. 2023;78:1769-1778.
    PubMed     Abstract available


  89. GOMIS-FONT MA, Sastre-Femenia MA, Taltavull B, Cabot G, et al
    In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2023;78:1785-1794.
    PubMed     Abstract available


  90. RONDA M, Padulles A, Grau I, Tubau F, et al
    Impact of a prospective audit and feedback antimicrobial stewardship programme on carbapenem consumption: a quasi-experimental study (IPANEMA study).
    J Antimicrob Chemother. 2023;78:1705-1710.
    PubMed     Abstract available


  91. BROUWER MSM, Zandbergen Van Essen A, Kant A, Rapallini M, et al
    Implementation of WGS analysis of ESBL-producing Escherichia coli within EU AMR monitoring in livestock and meat.
    J Antimicrob Chemother. 2023;78:1701-1704.
    PubMed     Abstract available


  92. URUSHIBARA N, Aung MS, Kawaguchiya M, Ohashi N, et al
    Genome analysis of an SCCmec element in ST9-MRSA from Myanmar with a unique mec gene complex and two ccr gene complexes (ccrA1B1 and ccrA5B7).
    J Antimicrob Chemother. 2023;78:1805-1806.
    PubMed    


  93. SORIANO A, Honore PM, Puerta-Alcalde P, Garcia-Vidal C, et al
    Invasive candidiasis: current clinical challenges and unmet needs in adult populations.
    J Antimicrob Chemother. 2023;78:1569-1585.
    PubMed     Abstract available


    June 2023
  94. YANG Q, Zhu Y, Schwarz S, Zhang W, et al
    Characterization of an optrA-harbouring unconventional circularizable structure located on a novel ICESa2603 family-like integrative and conjugative element ICESsuHN38 in Streptococcus suis.
    J Antimicrob Chemother. 2023 Jun 30:dkad205. doi: 10.1093.
    PubMed     Abstract available


  95. ANDO N, Mizushima D, Takano M, Mitobe M, et al
    Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study.
    J Antimicrob Chemother. 2023 Jun 28:dkad208. doi: 10.1093.
    PubMed     Abstract available


  96. DEPLANO A, Hallin M, Bustos Sierra N, Michel C, et al
    Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium.
    J Antimicrob Chemother. 2023 Jun 26:dkad204. doi: 10.1093.
    PubMed     Abstract available


  97. MARCHANDIN H, Anjou C, Poulen G, Freeman J, et al
    In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile.
    J Antimicrob Chemother. 2023 Jun 23:dkad194. doi: 10.1093.
    PubMed     Abstract available


  98. KAKOOZA F, Golparian D, Matoga M, Maseko V, et al
    Genomic surveillance and antimicrobial resistance determinants in Neisseria gonorrhoeae isolates from Uganda, Malawi and South Africa, 2015-20.
    J Antimicrob Chemother. 2023 Jun 23:dkad193. doi: 10.1093.
    PubMed     Abstract available


  99. SIMJEE S, Tice G
    The risk-benefit balance of resistance to ionophores in Enterococcus faecium and Enterococcus faecalis for ionophore coccidiostats in broiler chickens.
    J Antimicrob Chemother. 2023 Jun 9:dkad183. doi: 10.1093.
    PubMed     Abstract available


  100. PIROLO M, Menezes M, Damborg P, Wegener A, et al
    In vitro and in vivo susceptibility to cefalexin and amoxicillin/clavulanate in canine low-level methicillin-resistant Staphylococcus pseudintermedius.
    J Antimicrob Chemother. 2023 Jun 9:dkad182. doi: 10.1093.
    PubMed     Abstract available


  101. NOWAKOWSKA J, Cameron DR, De Martino A, Kuhn J, et al
    Evaluation of the microbiota-sparing properties of the anti-staphylococcal antibiotic afabicin.
    J Antimicrob Chemother. 2023 Jun 9:dkad181. doi: 10.1093.
    PubMed     Abstract available


  102. CHEN Y, Sun L, Hong Y, Chen M, et al
    Exploring the third-generation tetracycline resistance of multidrug-resistant livestock-associated methicillin-resistant Staphylococcus aureus ST9 across healthcare settings in China.
    J Antimicrob Chemother. 2023 Jun 8:dkad174. doi: 10.1093.
    PubMed     Abstract available


  103. QIAN C, Ma Z, Feng L, Guo W, et al
    Emergence of tet(X2) in Acinetobacter pittii confers clinical resistance to tigecycline.
    J Antimicrob Chemother. 2023;78:1543-1546.
    PubMed     Abstract available


  104. GATTI M, Pea F
    Comment on: pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections.
    J Antimicrob Chemother. 2023;78:1556-1557.
    PubMed    


  105. WORTMAN JM, Leegwater E, Van Lammeren-Venema D, Van Nieuwkoop C, et al
    Drug-drug interaction: decreased posaconazole trough concentrations during concomitant flucloxacillin treatment.
    J Antimicrob Chemother. 2023;78:1471-1475.
    PubMed     Abstract available


  106. DATTA S
    The conundrum of bacteria-specific antibiotics.
    J Antimicrob Chemother. 2023;78:1354-1358.
    PubMed     Abstract available


  107. SOJO-DORADO J, Lopez-Hernandez I, Hernandez-Torres A, Retamar-Gentil P, et al
    Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial.
    J Antimicrob Chemother. 2023 Jun 1:dkad147. doi: 10.1093.
    PubMed     Abstract available


    May 2023
  108. CINTHI M, Massacci FR, Coccitto SN, Albini E, et al
    Characterization of a prophage and a defective integrative conjugative element carrying the optrA gene in linezolid-resistant Streptococcus dysgalactiae subsp. equisimilis isolates from pigs, Italy.
    J Antimicrob Chemother. 2023 May 31:dkad164. doi: 10.1093.
    PubMed     Abstract available


  109. COCCITTO SN, Massacci FR, Cinthi M, Albini E, et al
    Co-location of the oxazolidinone resistance poxtA2 and cfr(D) genes on a multiresistance plasmid from a porcine Streptococcus dysgalactiae subsp. equisimilis, Italy.
    J Antimicrob Chemother. 2023 May 30:dkad169. doi: 10.1093.
    PubMed    


  110. LALANNE S, Cattoir V, Guerin F, Verdier MC, et al
    Differential response to antibiotic therapy in staphylococcal infective endocarditis: contribution of an ex vivo model.
    J Antimicrob Chemother. 2023 May 30:dkad155. doi: 10.1093.
    PubMed     Abstract available


  111. VASIKASIN V, Panuvatvanich B, Rawson TM, Holmes AH, et al
    Towards optimizing carbapenem selection in stewardship strategies: a prospective propensity score-matched study of ertapenem versus class 2 carbapenems for empirical treatment of third-generation cephalosporin-resistant Enterobacterales bacteraemia.
    J Antimicrob Chemother. 2023 May 30:dkad165. doi: 10.1093.
    PubMed     Abstract available


  112. SEALEY JE, Saunders R, Horspool T, Barrows MG, et al
    Molecular ecology of highest priority critically important antibiotic resistant Escherichia coli from mammals housed at an urban zoo.
    J Antimicrob Chemother. 2023 May 30:dkad148. doi: 10.1093.
    PubMed     Abstract available



  113. Correction to: Comparative effectiveness of beta-lactams for empirical treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective cohort study.
    J Antimicrob Chemother. 2023 May 23:dkad153. doi: 10.1093.
    PubMed    


  114. SHEN W, Zhang R, Cai J
    Co-occurrence of multiple plasmid-borne linezolid resistance genes-optrA, cfr, poxtA2 and cfr(D) in an Enterococcus faecalis isolate from retail meat.
    J Antimicrob Chemother. 2023 May 20:dkad142. doi: 10.1093.
    PubMed     Abstract available


  115. SANDOVAL MM, Bardach A, Rojas-Roque C, Alconada T, et al
    Antimicrobial resistance of Neisseria gonorrhoeae in Latin American countries: a systematic review.
    J Antimicrob Chemother. 2023 May 16:dkad071. doi: 10.1093.
    PubMed     Abstract available


  116. SCHELLENBERG JJ, Adam HJ, Baxter MR, Karlowsky JA, et al
    Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20.
    J Antimicrob Chemother. 2023;78.
    PubMed     Abstract available


  117. GOLDEN AR, Adam HJ, Karlowsky JA, Baxter M, et al
    Genomic investigation of the most common Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-2020.
    J Antimicrob Chemother. 2023;78.
    PubMed     Abstract available


  118. ADAM HJ, Karlowsky JA, Baxter MR, Schellenberg J, et al
    Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-2020.
    J Antimicrob Chemother. 2023;78.
    PubMed     Abstract available


  119. ZHANEL GG, Lynch JP, Adam HJ
    Streptococcus pneumoniae serotyping and antimicrobial susceptibility: assessment for vaccine efficacy in Canada after the introduction of PCV13.
    J Antimicrob Chemother. 2023;78.
    PubMed     Abstract available


  120. ALFORD MA, Karlowsky JA, Adam HJ, Baxter MR, et al
    Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-2020.
    J Antimicrob Chemother. 2023;78.
    PubMed     Abstract available


  121. ELIAS R, Spadar A, Hendrickx APA, Bonnin RA, et al
    Emergence of KPC-3- and OXA-181-producing ST13 and ST17 Klebsiella pneumoniae in Portugal: genomic insights on national and international dissemination.
    J Antimicrob Chemother. 2023;78:1300-1308.
    PubMed     Abstract available


  122. SIMJEE S, Gould G, Maduro L, Boulianne M, et al
    No change in avilamycin (Surmax(R) Premix) minimum inhibitory concentration for Clostridium perfringens isolates recovered from poultry up to 7 years post-approval in Canada.
    J Antimicrob Chemother. 2023;78:1278-1281.
    PubMed     Abstract available


  123. GONZALEZ C, Volland H, Oueslati S, Niol L, et al
    Evaluation of a new rapid immunochromatographic assay for the detection of GES-producing Gram-negative bacteria.
    J Antimicrob Chemother. 2023;78:1282-1287.
    PubMed     Abstract available


  124. CASTILLO-POLO JA, Hernandez-Garcia M, Morosini MI, Perez-Viso B, et al
    Outbreak by KPC-62-producing ST307 Klebsiella pneumoniae isolates resistant to ceftazidime/avibactam and cefiderocol in a university hospital in Madrid, Spain.
    J Antimicrob Chemother. 2023;78:1259-1264.
    PubMed     Abstract available


  125. ALONSO-GARCIA I, Vazquez-Ucha JC, Lasarte-Monterrubio C, Gonzalez-Mayo E, et al
    Simultaneous and divergent evolution of resistance to cephalosporin/beta-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
    J Antimicrob Chemother. 2023;78:1195-1200.
    PubMed     Abstract available


  126. JIA M, Zhou W, Luo D, Xue H, et al
    Calcium-binding motif-mediated binding of redundant calcium offers a chimeolysin enhanced bactericidal activity and extended host range under physiological conditions.
    J Antimicrob Chemother. 2023;78:1182-1190.
    PubMed     Abstract available


    April 2023
  127. DASHTBANI-ROOZBEHANI A, Chitsaz M, Brown MH
    The role of TMS 12 in the staphylococcal multidrug efflux protein QacA.
    J Antimicrob Chemother. 2023 Apr 26:dkad121. doi: 10.1093.
    PubMed     Abstract available


  128. DANESHNIA F, Hilmioglu-Polat S, Ilkit M, Fuentes D, et al
    Whole-genome sequencing confirms a persistent candidaemia clonal outbreak due to multidrug-resistant Candida parapsilosis.
    J Antimicrob Chemother. 2023 Apr 26:dkad112. doi: 10.1093.
    PubMed     Abstract available


  129. HENDERSON A, Cheng MP, Chew KL, Coombs GW, et al
    A multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus.
    J Antimicrob Chemother. 2023 Apr 18:dkad116. doi: 10.1093.
    PubMed     Abstract available


  130. BEREDAKI MI, Arendrup MC, Andes D, Meletiadis J, et al
    Development of an in vitro pharmacokinetic/pharmacodynamic model in the presence of serum for studying micafungin activity against Candida albicans: a need for revision of CLSI susceptibility breakpoints.
    J Antimicrob Chemother. 2023 Apr 18:dkad096. doi: 10.1093.
    PubMed     Abstract available


  131. LAFAURIE M, Montlahuc C, Kerneis S, de Lastours V, et al
    Efficacy of vancomycin lock therapy for totally implantable venous access port-related infection due to coagulase-negative staphylococci in 100 patients with cancer.
    J Antimicrob Chemother. 2023 Apr 4:dkad083. doi: 10.1093.
    PubMed     Abstract available


  132. SALEHI M, Farbod F, Khalili H, Rahmani H, et al
    Comparing efficacy and safety of high-dose and standard-dose rifampicin in the treatment of brucellosis: a randomized clinical trial.
    J Antimicrob Chemother. 2023;78:1084-1091.
    PubMed     Abstract available


  133. LU B, Wong M, Ha D, Bounthavong M, et al
    Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients.
    J Antimicrob Chemother. 2023;78:1009-1014.
    PubMed     Abstract available


  134. KUFEL WD, Hitchcock AM, Delbalso AN, Paolino KM, et al
    Evaluation of fidaxomicin use in patients with a macrolide allergy/intolerance.
    J Antimicrob Chemother. 2023;78:1127-1128.
    PubMed    


  135. SPERNOVASILIS N, Kritsotakis EI, Mathioudaki A, Vouidaski A, et al
    A carbapenem-focused antimicrobial stewardship programme implemented during the COVID-19 pandemic in a setting of high endemicity for multidrug-resistant Gram-negative bacteria.
    J Antimicrob Chemother. 2023;78:1000-1008.
    PubMed     Abstract available


    March 2023
  136. DIERIKX C, Hengeveld P, Witteveen S, van Hoek A, et al
    Genomic comparison of mecC-carrying methicillin-resistant Staphylococcus aureus from hedgehogs and humans in the Netherlands.
    J Antimicrob Chemother. 2023 Mar 30:dkad047. doi: 10.1093.
    PubMed     Abstract available


  137. CAREY GB, Holleck JL, Ein Alshaeba S, Jayakrishnan R, et al
    Estimated mortality with early empirical antibiotic coverage of methicillin-resistant Staphylococcus aureus in hospitalized patients with bacterial infections: a systematic review and meta-analysis.
    J Antimicrob Chemother. 2023 Mar 25:dkad078. doi: 10.1093.
    PubMed     Abstract available


  138. KIME L, Waring T, Mohamad M, Mann BF, et al
    Resistance to antibacterial antifolates in multidrug-resistant Staphylococcus aureus: prevalence estimates and genetic basis.
    J Antimicrob Chemother. 2023 Mar 20:dkad063. doi: 10.1093.
    PubMed     Abstract available


  139. YAMAGUCHI R, Yamamoto T, Okamoto K, Harada S, et al
    Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative study.
    J Antimicrob Chemother. 2023 Mar 15:dkad079. doi: 10.1093.
    PubMed     Abstract available


  140. BUIS DTP, van der Vaart TW, Prins JM, van der Meer JTM, et al
    Comparative effectiveness of beta-lactams for empirical treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective cohort study.
    J Antimicrob Chemother. 2023 Mar 10:dkad057. doi: 10.1093.
    PubMed     Abstract available


  141. WATKINS RR, Thapaliya D, Lemonovich TL, Bonomo RA, et al
    Gepotidacin: a novel, oral, 'first-in-class' triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea.
    J Antimicrob Chemother. 2023 Mar 8:dkad060. doi: 10.1093.
    PubMed     Abstract available


  142. SPADARI CC, Lanser DM, Araujo MV, De Jesus DFF, et al
    Oral delivery of brain-targeted miltefosine-loaded alginate nanoparticles functionalized with polysorbate 80 for the treatment of cryptococcal meningitis.
    J Antimicrob Chemother. 2023 Mar 7:dkad053. doi: 10.1093.
    PubMed     Abstract available


  143. HEIL EL, Claeys KC, Kline EG, Rogers TM, et al
    Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients.
    J Antimicrob Chemother. 2023 Mar 3:dkad042. doi: 10.1093.
    PubMed     Abstract available


  144. ESCUDERO-SANCHEZ R, Rubio Martin E, Vizcarra P, Braojos Sanchez F, et al
    Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence of Clostridioides difficile infection: a propensity score analysis.
    J Antimicrob Chemother. 2023;78:823-827.
    PubMed     Abstract available


  145. MCCURDY S, Halasohoris SA, Babyak AL, Lembirik S, et al
    Efficacy of delafloxacin against the biothreat pathogen Bacillus anthracis.
    J Antimicrob Chemother. 2023;78:810-816.
    PubMed     Abstract available


  146. DING ZH, Huang Y, Chen JN, Luo LS, et al
    A randomized superiority clinical trial: metronidazole improved the efficacy of high-dose dual therapy in Helicobacter pylori rescue treatment.
    J Antimicrob Chemother. 2023;78:828-831.
    PubMed     Abstract available


  147. FRESAN D, Luque S, Benitez-Cano A, Sorli L, et al
    Pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections.
    J Antimicrob Chemother. 2023;78:678-683.
    PubMed     Abstract available


  148. NUNN R, Clifford C, Merali Z
    Successful treatment of recurrent Clostridioides difficile infection by administration of crushed fidaxomicin via gastro-jejunal tube.
    J Antimicrob Chemother. 2023;78:850-851.
    PubMed    


    February 2023
  149. GUO Y, Han R, Zhang G, Yang Q, et al
    Setting of the tentative epidemiological cut-off values of contezolid for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae and Streptococcus agalactiae.
    J Antimicrob Chemother. 2023 Feb 28:dkad045. doi: 10.1093.
    PubMed     Abstract available


  150. KANEKO H, Yanagi Y, Otake S, Sato M, et al
    The emerging threat of methicillin-resistant Staphylococcus aureus (MRSA) clone ST22-PT, carrying both Panton-Valentine leucocidin and toxic shock syndrome toxin 1 genes.
    J Antimicrob Chemother. 2023 Feb 23:dkad039. doi: 10.1093.
    PubMed     Abstract available


  151. GUMBO T, Srivastava S, Deshpande D, Pasipanodya JG, et al
    Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.
    J Antimicrob Chemother. 2023 Feb 16:dkad029. doi: 10.1093.
    PubMed     Abstract available


  152. BELLOUARD R, Rambaud A, Delaunay C, Dailly E, et al
    Development and validation of a dosing nomogram for continuous infusion cloxacillin in infective endocarditis.
    J Antimicrob Chemother. 2023 Feb 10:dkad030. doi: 10.1093.
    PubMed     Abstract available


  153. MORENO-MINGORANCE A, Mir-Cros A, Goterris L, Rodriguez-Garrido V, et al
    Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020-21: outbreak of XRD Shigella sonnei and dissemination of ESBL-producing Shigella flexneri.
    J Antimicrob Chemother. 2023 Feb 10:dkad031. doi: 10.1093.
    PubMed     Abstract available


  154. CHEN H, Tao S, Li N, Zhu Q, et al
    Anti-restriction protein ArdA promotes clinical Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae spread and its molecular mechanism.
    J Antimicrob Chemother. 2023;78:521-530.
    PubMed     Abstract available


  155. BAE S, Kim ES, Lee YW, Jung J, et al
    Clinical and microbiological characteristics of rifampicin-resistant MRSA bacteraemia.
    J Antimicrob Chemother. 2023;78:531-539.
    PubMed     Abstract available


  156. YOUENOU B, Martins Simoes P, Tristan A, Farfour E, et al
    Linezolid resistance: detection of the cfr(B) gene in French clinical MRSA strains.
    J Antimicrob Chemother. 2023;78:445-449.
    PubMed     Abstract available


  157. LI Y, Liu Q, She J, Qiu Y, et al
    IS26-mediated in vivo acquisition of blaKPC-2 in an ST11-K64 Klebsiella pneumoniae isolate from a senile inpatient.
    J Antimicrob Chemother. 2023;78:550-553.
    PubMed    


  158. VALLEE M, Harding C, Hall J, Aldridge PD, et al
    Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates.
    J Antimicrob Chemother. 2023;78:373-379.
    PubMed     Abstract available


    January 2023
  159. HU J, Chen L, Li G, Pan Y, et al
    Prevalence and genetic characteristics of fosB-positive Staphylococcus aureus in duck farms in Guangdong, China in 2020.
    J Antimicrob Chemother. 2023 Jan 24:dkad014. doi: 10.1093.
    PubMed     Abstract available


  160. ROBSON C, Tan B, Stuart R, Nicholls S, et al
    A systematic review of optimal pharmacokinetic/pharmacodynamic parameters for beta-lactam therapy in infective endocarditis.
    J Antimicrob Chemother. 2023 Jan 24:dkad005. doi: 10.1093.
    PubMed     Abstract available


  161. CHEN L, Hua J, Hong SJ, Yuan CY, et al
    Comparison of the relative efficacy of beta-lactam/beta-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational coh
    J Antimicrob Chemother. 2023 Jan 24:dkac448. doi: 10.1093.
    PubMed     Abstract available


  162. LI XX, Zhang FQ, Wang S, Duan XC, et al
    Streptococcus suis prophage lysin as a new strategy for combating streptococci-induced mastitis and Streptococcus suis infection.
    J Antimicrob Chemother. 2023 Jan 20:dkad006. doi: 10.1093.
    PubMed     Abstract available


  163. AL JANABI J, Tevell S, Sieber RN, Stegger M, et al
    Emerging resistance in Staphylococcus epidermidis during dalbavancin exposure: a case report and in vitro analysis of isolates from prosthetic joint infections.
    J Antimicrob Chemother. 2023 Jan 6:dkac434. doi: 10.1093.
    PubMed     Abstract available


    December 2022
  164. POUGET C, Pantel A, Dunyach-Remy C, Magnan C, et al
    Antimicrobial activity of antibiotics on biofilm formed by Staphylococcus aureus and Pseudomonas aeruginosa in an open microfluidic model mimicking the diabetic foot environment.
    J Antimicrob Chemother. 2022 Dec 28:dkac438. doi: 10.1093.
    PubMed     Abstract available


  165. ZENG W, Han Y, Zheng X, Yao Z, et al
    Evaluation of resazurin microplate method for rapid detection of vancomycin and linezolid resistance in Enterococcus faecalis and Enterococcus faecium clinical isolates.
    J Antimicrob Chemother. 2022 Dec 28:dkac415. doi: 10.1093.
    PubMed     Abstract available


  166. BISHOP EJ, Tiruvoipati R
    Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines.
    J Antimicrob Chemother. 2022;78:21-30.
    PubMed     Abstract available


  167. FRIMODT-MOLLER N, Simonsen GS, Larsen AR, Kahlmeter G, et al
    Pivmecillinam, the paradigm of an antibiotic with low resistance rates in Escherichia coli urine isolates despite high consumption.
    J Antimicrob Chemother. 2022;78:289-295.
    PubMed     Abstract available


  168. MAUCK CK, Atiee GJ, McCulloh J, Reynolds L, et al
    A Phase 1 pharmacokinetic study of a single-dose bioadhesive clindamycin 2% gel for bacterial vaginosis.
    J Antimicrob Chemother. 2022;78:257-262.
    PubMed     Abstract available


  169. WU K, Wang J, Feng H, Li R, et al
    Complete genome sequence and characterization of Clostridium perfringens type D carrying optrA-plasmid and Tn6218-like transposon.
    J Antimicrob Chemother. 2022;78:311-313.
    PubMed    


  170. ZHAO B, Han H, He K, Hou WF, et al
    Decreased cyclic-AMP caused by ATP contributes to fosfomycin heteroresistance in avian Escherichia coli.
    J Antimicrob Chemother. 2022;78:216-224.
    PubMed     Abstract available


  171. ABD ALGAFFAR SO, Verbon A, Khalid SA, van de Sande WWJ, et al
    Development and validation of a resazurin assay for in vitro susceptibility testing of Actinomadura madurae: a common causative agent of actinomycetoma.
    J Antimicrob Chemother. 2022;78:155-160.
    PubMed     Abstract available


  172. GOLPARIAN D, Jacobsson S, Sanchez-Buso L, Bazzo ML, et al
    GyrB in silico mining in 27 151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility.
    J Antimicrob Chemother. 2022;78:150-154.
    PubMed     Abstract available


  173. MANTZOURANI E, Wasag D, Cannings-John R, Ahmed H, et al
    Characteristics of the sore throat test and treat service in community pharmacies (STREP) in Wales: cross-sectional analysis of 11 304 consultations using anonymized electronic pharmacy records.
    J Antimicrob Chemother. 2022;78:84-92.
    PubMed     Abstract available


  174. ANTONELLO RM, Canetti D, Riccardi N
    Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review.
    J Antimicrob Chemother. 2022;78:52-77.
    PubMed     Abstract available


  175. WAN TW, Yeo HH, Lee TF, Huang YT, et al
    Molecular epidemiology of bacteraemic vancomycin-resistant Enterococcus faecium isolates and in vitro activities of SC5005 and other comparators against these isolates collected from a medical centre in northern Taiwan, 2019-2020.
    J Antimicrob Chemother. 2022 Dec 17:dkac414. doi: 10.1093.
    PubMed     Abstract available


  176. XUAN H, Xia L, Schwarz S, Jia H, et al
    Various mobile genetic elements carrying optrA in Enterococcus faecium and Enterococcus faecalis isolates from swine within the same farm.
    J Antimicrob Chemother. 2022 Dec 12:dkac421. doi: 10.1093.
    PubMed     Abstract available


  177. XIAO J, Huang J, Xue X, Wang C, et al
    Novel cassette chromosome recombinases CcrA8B9 catalyse the excision and integration of the staphylococcal cassette chromosome mec element.
    J Antimicrob Chemother. 2022 Dec 8:dkac410. doi: 10.1093.
    PubMed     Abstract available


    November 2022
  178. LE MOIGNE V, Blouquit-Laye S, Desquesnes A, Girard-Misguich F, et al
    Liposomal amikacin and Mycobacterium abscessus: intimate interactions inside eukaryotic cells.
    J Antimicrob Chemother. 2022;77:3496-3503.
    PubMed     Abstract available


  179. MAXWELL DN, Kim J, Pybus CA, White L, et al
    Clinically undetected polyclonal heteroresistance among Pseudomonas aeruginosa isolated from cystic fibrosis respiratory specimens.
    J Antimicrob Chemother. 2022;77:3321-3330.
    PubMed     Abstract available


  180. SPRUTE R, Grothe JH, Heringer S, Cornely OA, et al
    Reason and reality-identifying barriers to patient enrolment for clinical trials in invasive candidiasis.
    J Antimicrob Chemother. 2022;77:3475-3481.
    PubMed     Abstract available


  181. WU YE, Zhao W
    'Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants'-authors' response.
    J Antimicrob Chemother. 2022;77:3525-3526.
    PubMed    


  182. CHEN L, Peirano G, Kreiswirth BN, Devinney R, et al
    Acquisition of genomic elements were pivotal for the success of Escherichia coli ST410.
    J Antimicrob Chemother. 2022;77:3399-3407.
    PubMed     Abstract available


  183. PAPAFOTIOU C, Roussos S, Sypsa V, Bampali S, et al
    Predictive score for patients with carbapenemase-producing enterobacterales colonization upon admission in a tertiary care hospital in an endemic area.
    J Antimicrob Chemother. 2022;77:3331-3339.
    PubMed     Abstract available


  184. BIEDRZYCKA M, Izdebski R, Urbanowicz P, Polanska M, et al
    MDR carbapenemase-producing Klebsiella pneumoniae of the hypervirulence-associated ST23 clone in Poland, 2009-19.
    J Antimicrob Chemother. 2022;77:3367-3375.
    PubMed     Abstract available


  185. VIANA AS, Botelho AMN, Feder A, Moustafa AM, et al
    High frequency of increased triclosan MIC among CC5 MRSA and risk of misclassification of the SCCmec into types.
    J Antimicrob Chemother. 2022;77:3340-3348.
    PubMed     Abstract available


  186. ZHANG W, Ran J, Shang L, Zhang L, et al
    Niclosamide as a repurposing drug against Gram-positive bacterial infections.
    J Antimicrob Chemother. 2022;77:3312-3320.
    PubMed     Abstract available


  187. IMANI S, Fitzgerald DA, Robinson PD, Selvadurai H, et al
    Personalized tobramycin dosing in children with cystic fibrosis: a comparative clinical evaluation of log-linear and Bayesian methods.
    J Antimicrob Chemother. 2022;77:3358-3366.
    PubMed     Abstract available


  188. STANDING JF
    Comment on: Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants.
    J Antimicrob Chemother. 2022;77:3524.
    PubMed    


  189. HOENIGL M, Lewis R, van de Veerdonk FL, Verweij PE, et al
    Liposomal amphotericin B-the future.
    J Antimicrob Chemother. 2022;77.
    PubMed     Abstract available


  190. BRUGGEMANN RJ, Jensen GM, Lass-Florl C
    Liposomal amphotericin B-the past.
    J Antimicrob Chemother. 2022;77.
    PubMed     Abstract available


  191. MAERTENS J, Pagano L, Azoulay E, Warris A, et al
    Liposomal amphotericin B-the present.
    J Antimicrob Chemother. 2022;77.
    PubMed     Abstract available


  192. GILL CM, Nicolau DP
    Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2022 Nov 22:dkac385. doi: 10.1093.
    PubMed     Abstract available


  193. LALANNE S, Guerin F, Flecher E, Cattoir V, et al
    Diffusion of amoxicillin into heart valves from infective endocarditis patients.
    J Antimicrob Chemother. 2022 Nov 15. pii: 6827952. doi: 10.1093.
    PubMed     Abstract available


  194. SARAVOLATZ LD, Pawlak J
    In vitro activity of fosfomycin alone and in combination against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid.
    J Antimicrob Chemother. 2022 Nov 14. pii: 6827318. doi: 10.1093.
    PubMed     Abstract available


  195. SPRUTE R, Van Braeckel E, Flick H, Hoenigl M, et al
    EQUAL CPA Score 2022: a tool to measure guideline adherence for chronic pulmonary aspergillosis.
    J Antimicrob Chemother. 2022 Nov 14. pii: 6827316. doi: 10.1093.
    PubMed     Abstract available


  196. EVANS RN, Harris J, Rogers CA, Macgowan AP, et al
    The effect of duration of therapy for treatment of Staphylococcus aureus blood stream infection: an application of cloning to deal with immortal-time bias in an analysis of data from a cohort study (BSI-FOO).
    J Antimicrob Chemother. 2022 Nov 8. pii: 6811497. doi: 10.1093.
    PubMed     Abstract available


  197. CASTRO BE, Rios R, Carvajal LP, Vargas ML, et al
    Multiomics characterization of methicillin-resistant Staphylococcus aureus (MRSA) isolates with heterogeneous intermediate resistance to vancomycin (hVISA) in Latin America.
    J Antimicrob Chemother. 2022 Nov 2. pii: 6794061. doi: 10.1093.
    PubMed     Abstract available


  198. KELENTSE N, Moyo S, Choga WT, Lechiile K, et al
    High concordance in plasma and CSF HIV-1 drug resistance mutations despite high cases of CSF viral escape in individuals with HIV-associated cryptococcal meningitis in Botswana.
    J Antimicrob Chemother. 2022 Nov 2. pii: 6794066. doi: 10.1093.
    PubMed     Abstract available


    October 2022
  199. TRIPONNEY P, Bour M, Beyrouthy R, Bonnet R, et al
    Role of megaplasmids and chromosomal integration in acquisition of CTX-M-encoding genes by Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2022;77:3194-3198.
    PubMed    


  200. WITT LS, Burd EM, Ozturk T, Satola SW, et al
    'Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance'-authors' response.
    J Antimicrob Chemother. 2022;77:3212.
    PubMed    


  201. NOTERMANS DW, Schoffelen AF, Landman F, Wielders CCH, et al
    A genetic cluster of OXA-244 carbapenemase-producing Escherichia coli ST38 with putative uropathogenicity factors in the Netherlands.
    J Antimicrob Chemother. 2022;77:3205-3208.
    PubMed    


  202. LASKO MJ, Tabor-Rennie JL, Nicolau DP, Kuti JL, et al
    Trimethoprim/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model.
    J Antimicrob Chemother. 2022;77:3187-3193.
    PubMed     Abstract available


  203. HERNANDEZ-GARCIA M, Garcia-Castillo M, Melo-Cristino J, Pinto MF, et al
    In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies).
    J Antimicrob Chemother. 2022;77:3163-3172.
    PubMed     Abstract available


  204. TAM VH, Merlau PR, Hudson CS, Kline EG, et al
    Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae.
    J Antimicrob Chemother. 2022;77:3130-3137.
    PubMed     Abstract available


  205. SUMI CD, Heffernan AJ, Naicker S, Cottrell K, et al
    Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Escherichia coli clinical isolates.
    J Antimicrob Chemother. 2022;77:3026-3034.
    PubMed     Abstract available


  206. PITT R, Boampong D, Day M, Jensen JS, et al
    Challenges of in vitro propagation and antimicrobial susceptibility testing of Mycoplasma genitalium.
    J Antimicrob Chemother. 2022;77:2901-2907.
    PubMed     Abstract available


  207. ZHAO X, Huang H, Yuan H, Yuan Z, et al
    A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections-authors' response.
    J Antimicrob Chemother. 2022;77:3210-3211.
    PubMed    


  208. BRUNA RE, Casal A, Bercovich B, Gramajo H, et al
    A natural product from Streptomyces targets PhoP and exerts antivirulence action against Salmonella enterica.
    J Antimicrob Chemother. 2022;77:3050-3063.
    PubMed     Abstract available


  209. WANG PL, Liu P, Zhang QW, Yuan WH, et al
    Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections.
    J Antimicrob Chemother. 2022;77:3000-3008.
    PubMed     Abstract available


  210. PALKOVICOVA J, Sukkar I, Delafuente J, Valcek A, et al
    Fitness effects of blaCTX-M-15-harbouring F2:A1:B- plasmids on their native Escherichia coli ST131 H30Rx hosts.
    J Antimicrob Chemother. 2022;77:2960-2963.
    PubMed     Abstract available


  211. AYFAN AKS, Macdonald J, Irwin AD, Zowawi HM, et al
    Proof-of-concept, rapid, instrument-free molecular detection of Neisseria gonorrhoeae and ciprofloxacin susceptibility.
    J Antimicrob Chemother. 2022;77:2933-2936.
    PubMed     Abstract available


  212. TANG K, Coombs S, Gwee A
    Frequency of drug-induced liver injury in children receiving anti-staphylococcal penicillins.
    J Antimicrob Chemother. 2022 Oct 7. pii: 6751029. doi: 10.1093.
    PubMed     Abstract available


  213. DE JONG A, El Garch F, Hocquet D, Prenger-Berninghoff E, et al
    European-wide antimicrobial resistance monitoring in commensal Escherichia coli isolated from healthy food animals between 2004 and 2018.
    J Antimicrob Chemother. 2022 Oct 7. pii: 6750681. doi: 10.1093.
    PubMed     Abstract available


    September 2022
  214. SHRESTHA R, Luterbach CL, Dai W, Komarow L, et al
    Characteristics of community-acquired carbapenem-resistant Enterobacterales.
    J Antimicrob Chemother. 2022;77:2763-2771.
    PubMed     Abstract available


  215. GROHS P, Vilfaillot A, Zahar JR, Barbut F, et al
    Faecal carriage of multidrug-resistant bacteria and associated risk factors: results from a point prevalence study.
    J Antimicrob Chemother. 2022;77:2667-2678.
    PubMed     Abstract available


  216. BRENCIANI A, Morroni G, Schwarz S, Giovanetti E, et al
    Oxazolidinones: mechanisms of resistance and mobile genetic elements involved.
    J Antimicrob Chemother. 2022;77:2596-2621.
    PubMed     Abstract available


  217. VOLLAND H, Balleste-Delpierre C, Szabo D, Gonzalez C, et al
    Rapid detection of CTX-M-type ESBLs and carbapenemases directly from biological samples using the BL-DetecTool.
    J Antimicrob Chemother. 2022;77:2867-2875.
    PubMed     Abstract available


  218. LONGSHAW CM, Santerre Henriksen A, Slover C, Yamano Y, et al
    Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance.
    J Antimicrob Chemother. 2022;77:2895-2896.
    PubMed    


  219. PATEL S, Chapagain M, Mason C, Gingrich M, et al
    Potency of the novel PolC DNA polymerase inhibitor CRS0540 in a disseminated Listeria monocytogenes intracellular hollow-fibre model.
    J Antimicrob Chemother. 2022;77:2876-2885.
    PubMed     Abstract available


  220. LASARTE-MONTERRUBIO C, Fraile-Ribot PA, Vazquez-Ucha JC, Cabot G, et al
    Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2022;77:2809-2815.
    PubMed     Abstract available


  221. KADO J, Salman S, Hand R, O'Brien M, et al
    Population pharmacokinetic study of benzathine penicillin G administration in Indigenous children and young adults with rheumatic heart disease in the Northern Territory, Australia.
    J Antimicrob Chemother. 2022;77:2679-2682.
    PubMed     Abstract available


  222. DE LAUZANNE A, Sreng N, Foucaud E, Sok T, et al
    Prevalence and factors associated with faecal carriage of extended-spectrum beta-lactamase-producing Enterobacterales among peripartum women in the community in Cambodia.
    J Antimicrob Chemother. 2022;77:2658-2666.
    PubMed     Abstract available


  223. DIAS SA, Pinto SN, Silva-Herdade AS, Cheneval O, et al
    A designed cyclic analogue of gomesin has potent activity against Staphylococcus aureus biofilms.
    J Antimicrob Chemother. 2022 Sep 29. pii: 6728340. doi: 10.1093.
    PubMed     Abstract available


  224. LI J, Fan Q, Zuo J, Xue B, et al
    Paeoniflorin combined with norfloxacin ameliorates drug-resistant Streptococcus suis infection.
    J Antimicrob Chemother. 2022 Sep 28. pii: 6730836. doi: 10.1093.
    PubMed     Abstract available


  225. RAMPACCI E, Felicetti T, Pietrella D, Sabatini S, et al
    Drug efflux transporters in Staphylococcus pseudintermedius: in silico prediction and characterization of resistance.
    J Antimicrob Chemother. 2022 Sep 28. pii: 6730837. doi: 10.1093.
    PubMed     Abstract available


  226. MELENDEZ-CARMONA MA, Mancheno-Losa M, Ruiz-Sorribas A, Munoz-Gallego I, et al
    Strain-to-strain variability among Staphylococcus aureus causing prosthetic joint infection drives heterogeneity in response to levofloxacin and rifampicin.
    J Antimicrob Chemother. 2022 Sep 19. pii: 6704758. doi: 10.1093.
    PubMed     Abstract available


  227. COLOMBO AL, De Almeida JN, Lewis RE, Kontoyiannis DP, et al
    Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis.
    J Antimicrob Chemother. 2022 Sep 5. pii: 6691804. doi: 10.1093.
    PubMed     Abstract available


  228. RIGATTO MH, Ramos F, Barros A, Pedroso S, et al
    Double-, single- and none-carbapenem-containing regimens for the treatment of carbapenem-resistant Enterobacterales (CRE) bloodstream infections: a retrospective cohort.
    J Antimicrob Chemother. 2022 Sep 1. pii: 6681124. doi: 10.1093.
    PubMed     Abstract available


    August 2022
  229. DIAZ-GARCIA J, Gomez A, Machado M, Alcala L, et al
    Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance and absence of Candida auris.
    J Antimicrob Chemother. 2022 Aug 29. pii: 6678135. doi: 10.1093.
    PubMed     Abstract available


  230. KONG FYS, Lo FWY, Hocking JS
    Treatment efficacy for rectal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials-authors' response.
    J Antimicrob Chemother. 2022;77:2576-2577.
    PubMed    


  231. GONZALEZ-DIAZ A, Berbel D, Ercibengoa M, Cercenado E, et al
    Genomic features of predominant non-PCV13 serotypes responsible for adult invasive pneumococcal disease in Spain.
    J Antimicrob Chemother. 2022;77:2389-2398.
    PubMed     Abstract available


  232. YAMADA K, Yoshizumi A, Nagasawa T, Aoki K, et al
    Molecular and biochemical characterization of novel PAM-like MBL variants, PAM-2 and PAM-3, from clinical isolates of Pseudomonas tohonis.
    J Antimicrob Chemother. 2022;77:2414-2418.
    PubMed     Abstract available


  233. PATERSON DL, Bassetti M, Motyl M, Johnson MG, et al
    Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
    J Antimicrob Chemother. 2022;77:2522-2531.
    PubMed     Abstract available


  234. MULLALLY C, Stubbs KA, Thai VC, Anandan A, et al
    Novel small molecules that increase the susceptibility of Neisseria gonorrhoeae to cationic antimicrobial peptides by inhibiting lipid A phosphoethanolamine transferase.
    J Antimicrob Chemother. 2022;77:2441-2447.
    PubMed     Abstract available


  235. PECHACEK J, Yakubu I, Vissichelli NC, Bruno D, et al
    Successful expanded access use of rezafungin, a novel echinocandin, to eradicate refractory invasive candidiasis in a liver transplant recipient.
    J Antimicrob Chemother. 2022;77:2571-2573.
    PubMed    


  236. YANG F, Gao S, Yan J, Lin X, et al
    Moenomycin is broadly active against multidrug-resistant Neisseria gonorrhoeae and clears an infection from a murine vaginal tract infection model.
    J Antimicrob Chemother. 2022;77:2461-2469.
    PubMed     Abstract available


  237. PARET R, Le Bourgeois A, Guillerm G, Tessoulin B, et al
    Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study.
    J Antimicrob Chemother. 2022;77:2546-2556.
    PubMed     Abstract available


  238. HSU YP, Chen LF, Chen FL, Liu YK, et al
    Comment on: Treatment efficacy for rectal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials.
    J Antimicrob Chemother. 2022;77:2574-2576.
    PubMed    


  239. WILSON RC, Arkell P, Riezk A, Gilchrist M, et al
    Addition of probenecid to oral beta-lactam antibiotics: a systematic review and meta-analysis.
    J Antimicrob Chemother. 2022;77:2364-2372.
    PubMed     Abstract available


  240. WITT LS, Steed DB, Burd EM, Ozturk T, et al
    Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance.
    J Antimicrob Chemother. 2022;77:2569-2571.
    PubMed    


  241. ISLAM K, Sime FB, Wallis SC, Bauer MJ, et al
    Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum beta-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
    J Antimicrob Chemother. 2022;77:2448-2455.
    PubMed     Abstract available


  242. YOON CH, Bartlett S, Stoesser N, Pouwels KB, et al
    Mortality risks associated with empirical antibiotic activity in Escherichia coli bacteraemia: an analysis of electronic health records.
    J Antimicrob Chemother. 2022;77:2536-2545.
    PubMed     Abstract available


  243. ZHAO L, Liu A, Li R, Zhang Z, et al
    High prevalence of blaTEM-135 and genetic epidemiology of blaTEM-135-carrying Neisseria gonorrhoeae isolates in Shandong, China, 2017-19.
    J Antimicrob Chemother. 2022;77:2406-2413.
    PubMed     Abstract available


  244. DANJOU W, Chabert P, Perpoint T, Pradat P, et al
    Necrotizing external otitis: analysis of relapse risk factors in 66 patients managed during a 12 year period.
    J Antimicrob Chemother. 2022;77:2532-2535.
    PubMed     Abstract available


  245. WANG G, Wu P, Tang R, Zhang W, et al
    Global prevalence of resistance to macrolides in Mycoplasma pneumoniae: a systematic review and meta-analysis.
    J Antimicrob Chemother. 2022;77:2353-2363.
    PubMed     Abstract available


  246. NUESCH-INDERBINEN M, Biggel M, Zurfluh K, Treier A, et al
    Faecal carriage of enterococci harbouring oxazolidinone resistance genes among healthy humans in the community in Switzerland.
    J Antimicrob Chemother. 2022 Aug 16. pii: 6667639. doi: 10.1093.
    PubMed     Abstract available


  247. FONG W, Timms V, Sim E, Pey K, et al
    Genomic and transcriptomic variation in Bordetella spp. following induction of erythromycin resistance.
    J Antimicrob Chemother. 2022 Aug 16. pii: 6667673. doi: 10.1093.
    PubMed     Abstract available


  248. ESCOLA-VERGE L, Rello P, Declerck C, Dubee V, et al
    Infective endocarditis in pregnant women without intravenous drug use: a multicentre retrospective case series.
    J Antimicrob Chemother. 2022 Aug 13. pii: 6664295. doi: 10.1093.
    PubMed     Abstract available


    July 2022
  249. ROGERS TR, Verweij PE, Castanheira M, Dannaoui E, et al
    Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.
    J Antimicrob Chemother. 2022;77:2053-2073.
    PubMed     Abstract available


  250. GASTINE S, Hempel G, Neely MN, Walsh TJ, et al
    Pharmacokinetic modelling of caspofungin to develop an extended dosing regimen in paediatric patients.
    J Antimicrob Chemother. 2022;77:2209-2216.
    PubMed     Abstract available


  251. SALLEM N, Hammami A, Mnif B
    Trends in human intestinal carriage of ESBL- and carbapenemase-producing Enterobacterales among food handlers in Tunisia: emergence of C1-M27-ST131 subclades, blaOXA-48 and blaNDM.
    J Antimicrob Chemother. 2022;77:2142-2152.
    PubMed     Abstract available


  252. KAKU N, Sasaki D, Ota K, Miyazaki T, et al
    Changing molecular epidemiology and characteristics of MRSA isolated from bloodstream infections: nationwide surveillance in Japan in 2019.
    J Antimicrob Chemother. 2022;77:2130-2141.
    PubMed     Abstract available


  253. CHUANG YC, Lin HY, Yang JL, Lin CY, et al
    Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin.
    J Antimicrob Chemother. 2022;77:2278-2287.
    PubMed     Abstract available


  254. CHEN L, van Rhee KP, Wasmann RE, Krekels EHJ, et al
    Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults.
    J Antimicrob Chemother. 2022;77:2217-2226.
    PubMed     Abstract available


  255. ROSCA AS, Castro J, Sousa LGV, Franca A, et al
    In vitro interactions within a biofilm containing three species found in bacterial vaginosis (BV) support the higher antimicrobial tolerance associated with BV recurrence.
    J Antimicrob Chemother. 2022;77:2183-2190.
    PubMed     Abstract available


  256. KUFEL WD, Abouelhassan Y, Steele JM, Gutierrez RL, et al
    Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis.
    J Antimicrob Chemother. 2022 Jul 23. pii: 6648989. doi: 10.1093.
    PubMed     Abstract available


  257. BUIS DTP, Prins JM, Betica-Radic L, de Boer MGJ, et al
    Current clinical practice in antibiotic treatment of Staphylococcus aureus bacteraemia: results from a survey in five European countries.
    J Antimicrob Chemother. 2022 Jul 23. pii: 6648977. doi: 10.1093.
    PubMed     Abstract available


  258. SEALEY JE, Hammond A, Mounsey O, Gould VC, et al
    Molecular ecology and risk factors for third-generation cephalosporin-resistant Escherichia coli carriage by dogs living in urban and nearby rural settings.
    J Antimicrob Chemother. 2022 Jul 20. pii: 6645196. doi: 10.1093.
    PubMed     Abstract available


  259. CHEN T, Zhao L, Liu Y, Wang Y, et al
    Mechanisms of high-level fosfomycin resistance in Staphylococcus aureus epidemic lineage ST5.
    J Antimicrob Chemother. 2022 Jul 15. pii: 6644783. doi: 10.1093.
    PubMed     Abstract available


  260. EMERAUD C, Godmer A, Girlich D, Vanparis O, et al
    Activity of mecillinam against carbapenem-resistant Enterobacterales.
    J Antimicrob Chemother. 2022 Jul 11. pii: 6639593. doi: 10.1093.
    PubMed     Abstract available


    June 2022
  261. TURNER NA, Xu A, Zaharoff S, Holland TL, et al
    Determination of plasma protein binding of dalbavancin.
    J Antimicrob Chemother. 2022;77:1899-1902.
    PubMed     Abstract available


  262. CHUMBITA M, Puerta-Alcalde P, Yanez L, Cuesta MA, et al
    Resistance to empirical beta-lactams recommended in febrile neutropenia guidelines in Gram-negative bacilli bloodstream infections in Spain: a multicentre study.
    J Antimicrob Chemother. 2022;77:2017-2023.
    PubMed     Abstract available


  263. TORRENS G, van der Schalk TE, Cortes-Lara S, Timbermont L, et al
    Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial.
    J Antimicrob Chemother. 2022;77:1862-1872.
    PubMed     Abstract available


  264. GOMEZ-SIMMONDS A, Annavajhala MK, Tang N, Rozenberg FD, et al
    Population structure of blaKPC-harbouring IncN plasmids at a New York City medical centre and evidence for multi-species horizontal transmission.
    J Antimicrob Chemother. 2022;77:1873-1882.
    PubMed     Abstract available


  265. ONG JJ, Aguirre I, Unemo M, Kong FYS, et al
    Comparison of gastrointestinal side effects from different doses of azithromycin for the treatment of gonorrhoea.
    J Antimicrob Chemother. 2022;77:2011-2016.
    PubMed     Abstract available


  266. ESCUDERO-SANCHEZ R, Muriel Garcia A, Garcia Fernandez S, Valencia Alijo A, et al
    Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study.
    J Antimicrob Chemother. 2022;77:1996-2002.
    PubMed     Abstract available


  267. DARLOW CA, Hope W
    Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales-authors' response.
    J Antimicrob Chemother. 2022;77:2047-2048.
    PubMed    


  268. STANDING JF
    Comment on: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales.
    J Antimicrob Chemother. 2022;77:2046-2047.
    PubMed    


  269. KAUL G, Akhir A, Shukla M, Rawat KS, et al
    Nitazoxanide potentiates linezolid against linezolid-resistant Staphylococcus aureus in vitro and in vivo.
    J Antimicrob Chemother. 2022 Jun 24. pii: 6617327. doi: 10.1093.
    PubMed     Abstract available


  270. IQBAL K, Rohde H, Huang J, Tikiso T, et al
    A pharmacokinetic-pharmacodynamic (PKPD) model-based analysis of tedizolid against enterococci using the hollow-fibre infection model.
    J Antimicrob Chemother. 2022 Jun 13. pii: 6607739. doi: 10.1093.
    PubMed     Abstract available


  271. GAUSI K, Chirehwa M, Ignatius EH, Court R, et al
    Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.
    J Antimicrob Chemother. 2022 Jun 9. pii: 6604654. doi: 10.1093.
    PubMed     Abstract available


    May 2022
  272. VUILLEMENOT JB, Bour M, Beyrouthy R, Bonnet R, et al
    Genomic analysis of CTX-M-115 and OXA-23/-72 co-producing Acinetobacter baumannii, and their potential to spread resistance genes by natural transformation.
    J Antimicrob Chemother. 2022;77:1542-1552.
    PubMed     Abstract available


  273. GAIBANI P, Bovo F, Bussini L, Lazzarotto T, et al
    Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
    J Antimicrob Chemother. 2022;77:1570-1577.
    PubMed     Abstract available


  274. PORMOHAMMAD A, Greening D, Turner RJ
    Synergism inhibition and eradication activity of silver nitrate/potassium tellurite combination against Pseudomonas aeruginosa biofilm.
    J Antimicrob Chemother. 2022;77:1635-1644.
    PubMed     Abstract available


  275. SPRUTE R, Bethe U, Chen SC, Cornely OA, et al
    EQUAL Trichosporon Score 2022: an ECMM score to measure QUALity of the clinical management of invasive Trichosporon infections.
    J Antimicrob Chemother. 2022;77:1779-1784.
    PubMed     Abstract available


  276. NAHA S, Sands K, Mukherjee S, Dutta S, et al
    A 12 year experience of colistin resistance in Klebsiella pneumoniae causing neonatal sepsis: two-component systems, efflux pumps, lipopolysaccharide modification and comparative phylogenomics.
    J Antimicrob Chemother. 2022;77:1586-1591.
    PubMed     Abstract available


  277. CABRERA R, Fernandez-Barat L, Vazquez N, Alcaraz-Serrano V, et al
    Resistance mechanisms and molecular epidemiology of Pseudomonas aeruginosa strains from patients with bronchiectasis.
    J Antimicrob Chemother. 2022;77:1600-1610.
    PubMed     Abstract available


  278. YEOH DK, Haeusler GM, McMullan BJ, Butters C, et al
    Antifungal use in children with acute leukaemia: state of current evidence and directions for future research.
    J Antimicrob Chemother. 2022;77:1508-1524.
    PubMed     Abstract available


  279. IZDEBSKI R, Biedrzycka M, Urbanowicz P, Papierowska-Kozdoj W, et al
    Multiple secondary outbreaks of NDM-producing Enterobacter hormaechei in the context of endemic NDM-producing Klebsiella pneumoniae.
    J Antimicrob Chemother. 2022;77:1561-1569.
    PubMed     Abstract available


  280. JAUNEIKAITE E, Honeyford K, Blandy O, Mosavie M, et al
    Bacterial genotypic and patient risk factors for adverse outcomes in Escherichia coli bloodstream infections: a prospective molecular epidemiological study.
    J Antimicrob Chemother. 2022;77:1753-1761.
    PubMed     Abstract available


  281. CHAPAGAIN M, Pasipanodya JG, Athale S, Bernal C, et al
    Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses.
    J Antimicrob Chemother. 2022;77:1694-1705.
    PubMed     Abstract available


  282. LUQUE-PAZ D, Bennis Y, Jaubert P, Dubee V, et al
    Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis.
    J Antimicrob Chemother. 2022;77:1787-1789.
    PubMed    


  283. SAKOULAS G
    Linezolid versus omadacycline in diabetic soft tissue infections: a signal of different adjunctive immunological properties?
    J Antimicrob Chemother. 2022;77:1503-1505.
    PubMed     Abstract available


  284. IWUJI C, Pillay D, Shamu P, Murire M, et al
    A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa.
    J Antimicrob Chemother. 2022 May 17. pii: 6586623. doi: 10.1093.
    PubMed     Abstract available


  285. WILLEKENS R, Puig-Asensio M, Suanzes P, Fernandez-Hidalgo N, et al
    Empirical use of beta-lactam/beta-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-weighted cohort study.
    J Antimicrob Chemother. 2022 May 12. pii: 6584695. doi: 10.1093.
    PubMed     Abstract available


  286. GOLPARIAN D, Kittiyaowamarn R, Paopang P, Sangprasert P, et al
    Genomic surveillance and antimicrobial resistance in Neisseria gonorrhoeae isolates in Bangkok, Thailand in 2018.
    J Antimicrob Chemother. 2022 May 11. pii: 6583486. doi: 10.1093.
    PubMed     Abstract available


    April 2022
  287. FLATEAU C, Riazi A, Cassard B, Camus M, et al
    Streptococcal and enterococcal endocarditis: time for individualized antibiotherapy?-authors' response.
    J Antimicrob Chemother. 2022 Apr 27. pii: 6574660. doi: 10.1093.
    PubMed    


  288. GARCIA-FIERRO R, Drapeau A, Dazas M, Saras E, et al
    Comparative phylogenomics of ESBL-, AmpC- and carbapenemase-producing Klebsiella pneumoniae originating from companion animals and humans.
    J Antimicrob Chemother. 2022;77:1263-1271.
    PubMed     Abstract available


  289. ABBOTT IJ, van Gorp E, Wyres KL, Wallis SC, et al
    Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.
    J Antimicrob Chemother. 2022;77:1324-1333.
    PubMed     Abstract available


  290. MILTGEN G, Martak D, Valot B, Kamus L, et al
    One Health compartmental analysis of ESBL-producing Escherichia coli on Reunion Island reveals partitioning between humans and livestock.
    J Antimicrob Chemother. 2022;77:1254-1262.
    PubMed     Abstract available


  291. BASTIDA C, Hernandez-Tejero M, Cariqueo M, Aziz F, et al
    Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections.
    J Antimicrob Chemother. 2022;77:1365-1371.
    PubMed     Abstract available


  292. MEI CY, Jiao X, Wu H, Wang ZY, et al
    Detection of cfr in Leclercia adecarboxylata from pig feed, China.
    J Antimicrob Chemother. 2022;77:1500-1502.
    PubMed    


  293. ZHANG X, Shi S, Yao Z, Zheng X, et al
    Antimicrobial peptide WAM-1: a promising antibacterial and anti-inflammatory drug against carbapenem-resistant Klebsiella pneumoniae.
    J Antimicrob Chemother. 2022 Apr 27. pii: 6574685. doi: 10.1093.
    PubMed     Abstract available


  294. TAIT JR, Barnett TC, Rogers KE, Lee WL, et al
    Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling.
    J Antimicrob Chemother. 2022 Apr 26. pii: 6573986. doi: 10.1093.
    PubMed     Abstract available


  295. LOPEZ-VARELA E, Abulfathi AA, Strydom N, Goussard P, et al
    Drug concentration at the site of disease in children with pulmonary tuberculosis.
    J Antimicrob Chemother. 2022 Apr 25. pii: 6573919. doi: 10.1093.
    PubMed     Abstract available


  296. CHAGNEAU CV, Alcouffe O, Grare M, Oswald E, et al
    Screening for beta-lactam resistance by penicillin G in the Streptococcus anginosus group challenged by rare strains with altered PBPs.
    J Antimicrob Chemother. 2022 Apr 25. pii: 6573466. doi: 10.1093.
    PubMed     Abstract available


  297. ENER B, Ergin C, Gulmez D, Agca H, et al
    Frequency of azole resistance in clinical and environmental strains of Aspergillus fumigatus in Turkey: a multicentre study.
    J Antimicrob Chemother. 2022 Apr 21. pii: 6571734. doi: 10.1093.
    PubMed     Abstract available


  298. SCHWENDENER S, Perreten V
    The bla and mec families of beta-lactam resistance genes in the genera Macrococcus, Mammaliicoccus and Staphylococcus: an in-depth analysis with emphasis on Macrococcus.
    J Antimicrob Chemother. 2022 Apr 21. pii: 6571732. doi: 10.1093.
    PubMed     Abstract available


  299. LIU C, Dong N, Zeng Y, Lu J, et al
    Co-transfer of last-line antibiotic resistance and virulence operons by an IncFIBk-FII-X3-ColKP3 hybrid plasmid in Klebsiella pneumoniae.
    J Antimicrob Chemother. 2022 Apr 21. pii: 6571571. doi: 10.1093.
    PubMed     Abstract available


  300. SIMOS PA, Holland DJ, Stewart A, Isler B, et al
    Clinical prediction scores and the utility of time to blood culture positivity in stratifying the risk of infective endocarditis in Staphylococcus aureus bacteraemia.
    J Antimicrob Chemother. 2022 Apr 15. pii: 6568605. doi: 10.1093.
    PubMed     Abstract available


  301. CORTES MF, Andre C, Martins Simoes P, Corvec S, et al
    Persistence of a multidrug-resistant worldwide-disseminated methicillin-resistant Staphylococcus epidermidis clone harbouring the cfr linezolid resistance gene in a French hospital with evidence of interspecies transfer to several Staphylococcus aureu
    J Antimicrob Chemother. 2022 Apr 15. pii: 6568602. doi: 10.1093.
    PubMed     Abstract available


  302. FUCHS F, Becerra-Aparicio F, Xanthopoulou K, Seifert H, et al
    In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract.
    J Antimicrob Chemother. 2022 Apr 12. pii: 6566767. doi: 10.1093.
    PubMed     Abstract available


  303. HARMER CJ, Lebreton F, Stam J, McGann PT, et al
    Complete genome of the extensively antibiotic-resistant GC1 Acinetobacter baumannii isolate MRSN 56 reveals a novel route to fluoroquinolone resistance.
    J Antimicrob Chemother. 2022 Apr 11. pii: 6566059. doi: 10.1093.
    PubMed     Abstract available


  304. GIULIANO S, Angelini J, Flammini S, Tascini C, et al
    Comment on: Streptococcal and enterococcal endocarditis: time for individualized antibiotherapy?
    J Antimicrob Chemother. 2022 Apr 4. pii: 6562960. doi: 10.1093.
    PubMed    


  305. CHAIBEN V, Yamada CH, Telles JP, de Andrade AP, et al
    A carbapenem-resistant Acinetobacter baumannii outbreak associated with a polymyxin shortage during the COVID pandemic: an in vitro and biofilm analysis of synergy between meropenem, gentamicin and sulbactam.
    J Antimicrob Chemother. 2022 Apr 4. pii: 6562691. doi: 10.1093.
    PubMed     Abstract available


    March 2022
  306. BIEZ L, Bonnin RA, Naas T, Dortet L, et al
    Characterization of VIM-1-, NDM-1- and OXA-48-producing Citrobacter freundii in France.
    J Antimicrob Chemother. 2022;77:1200-1202.
    PubMed    


  307. MUDDE SE, Upton AM, Lenaerts A, Bax HI, et al
    Delamanid or pretomanid? A Solomonic judgement!
    J Antimicrob Chemother. 2022;77:880-902.
    PubMed     Abstract available


  308. GOMIS-FONT MA, Cabot G, Lopez-Arguello S, Zamorano L, et al
    Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.
    J Antimicrob Chemother. 2022;77:957-968.
    PubMed     Abstract available


  309. PANT N, Wallis SC, Roberts JA, Eisen DP, et al
    In vitro effect of synovial fluid from patients undergoing arthroplasty surgery on MRSA biofilm formation.
    J Antimicrob Chemother. 2022;77:1041-1044.
    PubMed     Abstract available


  310. EMERAUD C, Petit C, Gauthier L, Bonnin RA, et al
    Emergence of VIM-producing Enterobacter cloacae complex in France between 2015 and 2018.
    J Antimicrob Chemother. 2022;77:944-951.
    PubMed     Abstract available


  311. REYNOLDS R, Mushtaq S, Allen MK, Horner C, et al
    Impact of changed co-amoxiclav susceptibility testing formats on apparent resistance rates for bloodstream Escherichia coli in a long-term surveillance.
    J Antimicrob Chemother. 2022;77:1206-1208.
    PubMed    


  312. FALCONE M, Tiseo G, Arcari G, Leonildi A, et al
    Spread of hypervirulent multidrug-resistant ST147 Klebsiella pneumoniae in patients with severe COVID-19: an observational study from Italy, 2020-21.
    J Antimicrob Chemother. 2022;77:1140-1145.
    PubMed     Abstract available


  313. WANG W, Hu Y, Baker M, Dottorini T, et al
    Novel SCCmec type XV (7A) and two pseudo-SCCmec variants in foodborne MRSA in China.
    J Antimicrob Chemother. 2022;77:903-909.
    PubMed     Abstract available


  314. LI D, Li P, Peng M, Zhao X, et al
    Transmission barrier of the blaKPC plasmid mediated by type I restriction-modification systems in Escherichia coli.
    J Antimicrob Chemother. 2022;77:952-956.
    PubMed     Abstract available


  315. MAGALLON A, Amoureux L, Garrigos T, Sonois M, et al
    Role of AxyABM overexpression in acquired resistance in Achromobacter xylosoxidans.
    J Antimicrob Chemother. 2022;77:926-929.
    PubMed     Abstract available


  316. MARTIN-LOECHES I, Timsit JF, Kollef MH, Wunderink RG, et al
    Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
    J Antimicrob Chemother. 2022;77:1166-1177.
    PubMed     Abstract available


  317. VEHRESCHILD MJGT, Ducher A, Louie T, Cornely OA, et al
    An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.
    J Antimicrob Chemother. 2022;77:1155-1165.
    PubMed     Abstract available


  318. TICKNER JA, Bradshaw CS, Murray GL, Whiley DM, et al
    Novel probe-based melting curve assays for the characterization of fluoroquinolone resistance in Mycoplasma genitalium.
    J Antimicrob Chemother. 2022 Mar 30. pii: 6555777. doi: 10.1093.
    PubMed     Abstract available


  319. LIANG J, Macesic N, Blakeway L
    Comment on: Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge?
    J Antimicrob Chemother. 2022 Mar 24. pii: 6553323. doi: 10.1093.
    PubMed    


  320. GEORGIOU PC, Arendrup MC, Meletiadis J
    Early phenotypic detection of fluconazole- and anidulafungin-resistant Candida glabrata isolates.
    J Antimicrob Chemother. 2022 Mar 22. pii: 6551886. doi: 10.1093.
    PubMed     Abstract available


  321. KIRCHHOFF L, Dittmer S, Furnica DT, Buer J, et al
    Inhibition of azole-resistant Aspergillus fumigatus biofilm at various formation stages by antifungal drugs, including olorofim.
    J Antimicrob Chemother. 2022 Mar 15. pii: 6548677. doi: 10.1093.
    PubMed     Abstract available


  322. CREMANNS M, Lange F, Gatermann SG, Pfennigwerth N, et al
    Effect of sigma E on carbapenem resistance in OXA-48-producing Klebsiella pneumoniae.
    J Antimicrob Chemother. 2022 Mar 10. pii: 6546017. doi: 10.1093.
    PubMed     Abstract available


  323. BATESON A, Ortiz Canseco J, McHugh TD, Witney AA, et al
    Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid.
    J Antimicrob Chemother. 2022 Mar 9. pii: 6544883. doi: 10.1093.
    PubMed     Abstract available


  324. UPTON CM, Steele CI, Maartens G, Diacon AH, et al
    Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB).
    J Antimicrob Chemother. 2022 Mar 8. pii: 6543975. doi: 10.1093.
    PubMed     Abstract available


  325. NEVILLE LF, Shalit I, Warn PA, Rendell JT, et al
    Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model.
    J Antimicrob Chemother. 2022 Mar 1. pii: 6539950. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  326. MELETIADIS J, Efstathiou I, van der Lee HAL, Astvad KMT, et al
    Spectrophotometric detection of azole-resistant Aspergillus fumigatus with the EUCAST broth microdilution method: is it time for automated MIC reading of EUCAST antifungal susceptibility testing of Aspergillus species?
    J Antimicrob Chemother. 2022 Feb 23. pii: 6534628. doi: 10.1093.
    PubMed     Abstract available


  327. BAE M, Jung J
    Short versus prolonged courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection: a retrospective study-authors' response.
    J Antimicrob Chemother. 2022;77:859-860.
    PubMed    


  328. BURY D, Wolfs TFW, Ter Heine R, Muilwijk EW, et al
    Pharmacokinetic evaluation of twice-a-week micafungin for prophylaxis of invasive fungal disease in children with acute lymphoblastic leukaemia: a prospective observational cohort study.
    J Antimicrob Chemother. 2022;77:699-703.
    PubMed     Abstract available


  329. FOSTERVOLD A, Hetland MAK, Bakksjo R, Bernhoff E, et al
    A nationwide genomic study of clinical Klebsiella pneumoniae in Norway 2001-15: introduction and spread of ESBLs facilitated by clonal groups CG15 and CG307.
    J Antimicrob Chemother. 2022;77:665-674.
    PubMed     Abstract available


  330. ALIABADI S, Jauneikaite E, Muller-Pebody B, Hope R, et al
    Exploring temporal trends and risk factors for resistance in Escherichia coli-causing bacteraemia in England between 2013 and 2018: an ecological study.
    J Antimicrob Chemother. 2022;77:782-792.
    PubMed     Abstract available


  331. HAGIYA H, Otsuka F
    Comment on: Short versus prolonged courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection: a retrospective study.
    J Antimicrob Chemother. 2022;77:857-858.
    PubMed    


  332. MARTELLI F, AbuOun M, Cawthraw S, Storey N, et al
    Detection of the transferable tigecycline resistance gene tet(X4) in Escherichia coli from pigs in the United Kingdom.
    J Antimicrob Chemother. 2022;77:846-848.
    PubMed    


  333. LUO H, Chen W, Mai Z, Yang J, et al
    Development and application of Cas13a-based diagnostic assay for Neisseria gonorrhoeae detection and azithromycin resistance identification.
    J Antimicrob Chemother. 2022;77:656-664.
    PubMed     Abstract available


  334. FIFER H, Schaefer U, Pitt R, Allen H, et al
    Use of genomics to investigate Neisseria gonorrhoeae antimicrobial susceptibility testing discrepancies.
    J Antimicrob Chemother. 2022;77:849-850.
    PubMed    


  335. KELLY J, Tysall L, Dewar S
    Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant Enterococcus faecium (VREfm).
    J Antimicrob Chemother. 2022 Feb 15. pii: 6528651. doi: 10.1093.
    PubMed     Abstract available


  336. CHUANG YC, Tseng TC, Wang JT, Lin CY, et al
    Influence of daptomycin dose and fosfomycin susceptibility on outcome of vancomycin-resistant Enterococcus faecium bloodstream infections treated with daptomycin and fosfomycin combination.
    J Antimicrob Chemother. 2022 Feb 10. pii: 6525717. doi: 10.1093.
    PubMed     Abstract available


  337. GOLDEN AR, Baxter M, Adam HJ, Martin I, et al
    PCV-15 and PPSV-23 coverage of invasive and respiratory tract Streptococcus pneumoniae, including MDR and XDR isolates: CANWARD 2007-20.
    J Antimicrob Chemother. 2022 Feb 10. pii: 6525856. doi: 10.1093.
    PubMed     Abstract available


  338. XU C, Wang N, Li D, Schwarz S, et al
    Recombination events that occur in a poxtA-carrying Enterococcus faecium during the conjugation process.
    J Antimicrob Chemother. 2022 Feb 8. pii: 6524123. doi: 10.1093.
    PubMed     Abstract available


  339. COCCITTO SN, Cinthi M, Fioriti S, Morroni G, et al
    Linezolid-resistant Enterococcus gallinarum isolate of swine origin carrying cfr, optrA and poxtA genes.
    J Antimicrob Chemother. 2022;77:331-337.
    PubMed     Abstract available


  340. MARR I, Swe K, Henderson A, Lacey JA, et al
    Cefazolin susceptibility of coagulase-negative staphylococci (CoNS) causing late-onset neonatal bacteraemia.
    J Antimicrob Chemother. 2022;77:338-344.
    PubMed     Abstract available


  341. EGAN SA, Kavanagh NL, Shore AC, Mollerup S, et al
    Genomic analysis of 600 vancomycin-resistant Enterococcus faecium reveals a high prevalence of ST80 and spread of similar vanA regions via IS1216E and plasmid transfer in diverse genetic lineages in Ireland.
    J Antimicrob Chemother. 2022;77:320-330.
    PubMed     Abstract available


  342. WASSERMAN S, Brust JCM, Abdelwahab MT, Little F, et al
    Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study.
    J Antimicrob Chemother. 2022 Feb 2. pii: 6520540. doi: 10.1093.
    PubMed     Abstract available


  343. SCHUSTER CF, Weber RE, Weig M, Werner G, et al
    Ultra-deep long-read sequencing detects IS-mediated gene duplications as a potential trigger to generate arrays of resistance genes and a mechanism to induce novel gene variants such as blaCTX-M-243.
    J Antimicrob Chemother. 2022;77:381-390.
    PubMed     Abstract available


  344. GUO CG, Jiang F, Cheung KS, Li B, et al
    Timing of prior exposure to antibiotics and failure of Helicobacter pylori eradication: a population-based study.
    J Antimicrob Chemother. 2022;77:517-523.
    PubMed     Abstract available


  345. KANESAKA I, Ohno A, Katsuse AK, Takahashi H, et al
    The emergence of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone by transfer of resistance from an oral Neisseria subflava reservoir of resistance.
    J Antimicrob Chemother. 2022;77:364-373.
    PubMed     Abstract available


  346. LIN EY, Adamson PC, Klausner JD
    Applying molecular algorithms to predict decreased susceptibility to ceftriaxone from a report of strains of Neisseria gonorrhoeae in Amsterdam, the Netherlands.
    J Antimicrob Chemother. 2022;77:534-536.
    PubMed    


    January 2022
  347. AMBROSE SJ, Evans BA, Hall RM
    Origin of the oxa235 carbapenem resistance gene found in transposon Tn6252.
    J Antimicrob Chemother. 2022 Jan 30. pii: 6517523. doi: 10.1093.
    PubMed    


  348. KIESWETTER NS, Ozturk M, Hlaka L, Chia JE, et al
    Intranasally administered S-MGB-364 displays antitubercular activity and modulates the host immune response to Mycobacterium tuberculosis infection.
    J Antimicrob Chemother. 2022 Jan 25. pii: 6515318. doi: 10.1093.
    PubMed     Abstract available


  349. ZOU G, Matuszewska M, Bai F, Wang S, et al
    Genomic analyses of Staphylococcus aureus isolated from yaks in Ganzi Tibetan Autonomous Prefecture, China.
    J Antimicrob Chemother. 2022 Jan 25. pii: 6515324. doi: 10.1093.
    PubMed     Abstract available


  350. FRENK S, Temkin E, Lurie-Weinberger MN, Keren-Paz A, et al
    Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance.
    J Antimicrob Chemother. 2022 Jan 25. pii: 6515327. doi: 10.1093.
    PubMed     Abstract available


  351. SEMPERE J, Gonzalez-Camacho F, Domenech M, Llamosi M, et al
    A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004-20 in Spain.
    J Antimicrob Chemother. 2022 Jan 19. pii: 6511705. doi: 10.1093.
    PubMed     Abstract available


  352. PAUNKOV A, Gutenbrunner K, Soki J, Leitsch D, et al
    Haemin deprivation renders Bacteroides fragilis hypersusceptible to metronidazole and cancels high-level metronidazole resistance.
    J Antimicrob Chemother. 2022 Jan 18. pii: 6510936. doi: 10.1093.
    PubMed     Abstract available


  353. MANTZOURANI E, Cannings-John R, Evans A, Ahmed H, et al
    To swab or not to swab? Using point-of-care tests to detect Group A Streptococcus infections as part of a Sore Throat Test and Treat service in community pharmacy.
    J Antimicrob Chemother. 2022 Jan 17. pii: 6509366. doi: 10.1093.
    PubMed     Abstract available


  354. GWEE A, Duffull SB, Daley AJ, Lim M, et al
    Identifying a therapeutic target for vancomycin against staphylococci in young infants.
    J Antimicrob Chemother. 2022 Jan 17. pii: 6509364. doi: 10.1093.
    PubMed     Abstract available


  355. THILL P, Robineau O, Roosen G, Patoz P, et al
    Rifabutin versus rifampicin bactericidal and antibiofilm activities against clinical strains of Staphylococcus spp. isolated from bone and joint infections.
    J Antimicrob Chemother. 2022 Jan 13. pii: 6506691. doi: 10.1093.
    PubMed     Abstract available


  356. GAILLARD T, Dupieux-Chabert C, Butin M, Dumitrescu O, et al
    Heterogeneous vancomycin resistance in Staphylococcus aureus does not predict development of vancomycin resistance upon vancomycin pressure.
    J Antimicrob Chemother. 2022 Jan 11. pii: 6503862. doi: 10.1093.
    PubMed     Abstract available


    December 2021
  357. KLAUKE P, Schwab F, Gastmeier P, Maechler F, et al
    The impact of non-antimicrobial drug agents on the acquisition of ESBL-producing Enterobacterales in non-critical care wards in a German university hospital: an exploratory, matched case-control study.
    J Antimicrob Chemother. 2021;77:229-236.
    PubMed     Abstract available


  358. FISCHER N, Maex M, Mattheus W, Van den Bossche A, et al
    Genomic epidemiology of persistently circulating MDR Shigella sonnei strains associated with men who have sex with men (MSM) in Belgium (2013-19).
    J Antimicrob Chemother. 2021;77:89-97.
    PubMed     Abstract available


  359. TIMMERMANS M, Bogaerts B, Vanneste K, De Keersmaecker SCJ, et al
    Large diversity of linezolid-resistant isolates discovered in food-producing animals through linezolid selective monitoring in Belgium in 2019.
    J Antimicrob Chemother. 2021;77:49-57.
    PubMed     Abstract available


  360. DE CARVALHO CCCR, Taglialegna A, Rosato AE
    Impact of PrsA on membrane lipid composition during daptomycin-resistance-mediated beta-lactam sensitization in clinical MRSA strains.
    J Antimicrob Chemother. 2021;77:135-147.
    PubMed     Abstract available


  361. YOON EJ, Kim HS, Woo H, Choi YJ, et al
    Trajectory of genetic alterations associated with colistin resistance in Acinetobacter baumannii during an in-hospital outbreak of infection.
    J Antimicrob Chemother. 2021;77:69-73.
    PubMed     Abstract available


  362. BAE M, Jeong Y, Bae S, Kim MJ, et al
    Short versus prolonged courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection: a retrospective study.
    J Antimicrob Chemother. 2021;77:223-228.
    PubMed     Abstract available


  363. BUCKLEY AM, Moura IB, Altringham J, Ewin D, et al
    The use of first-generation cephalosporin antibiotics, cefalexin and cefradine, is not associated with induction of simulated Clostridioides difficile infection.
    J Antimicrob Chemother. 2021;77:148-154.
    PubMed     Abstract available


  364. CAMERON-MCDERMOTT SM, Barrow GJ, Webster AM, De La Haye CO, et al
    Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and syndromic treatment of men with urethral discharge in Kingston, Jamaica, 2018-19.
    J Antimicrob Chemother. 2021;77:218-222.
    PubMed     Abstract available


  365. WILLEMS RPJ, van Dijk K, Dierikx CM, Twisk JWR, et al
    Gastric acid suppression, lifestyle factors and intestinal carriage of ESBL and carbapenemase-producing Enterobacterales: a nationwide population-based study.
    J Antimicrob Chemother. 2021;77:237-245.
    PubMed     Abstract available


  366. STEMLER J, Lackner M, Chen SC, Hoenigl M, et al
    EQUAL Score Scedosporiosis/Lomentosporiosis 2021: a European Confederation of Medical Mycology (ECMM) tool to quantify guideline adherence.
    J Antimicrob Chemother. 2021;77:253-258.
    PubMed     Abstract available


  367. NURJADI D, Klein S, Hannesen J, Heeg K, et al
    Molecular analysis of an increase in trimethoprim/sulfamethoxazole-resistant MRSA reveals multiple introductions into a tertiary care hospital, Germany 2012-19.
    J Antimicrob Chemother. 2021;77:38-48.
    PubMed     Abstract available


  368. JIAN Y, Li T, Zhao L, Zhao N, et al
    Regulation of bla system in ST59-related oxacillin-susceptible mecA-positive Staphylococcus aureus.
    J Antimicrob Chemother. 2021 Dec 16. pii: 6464066. doi: 10.1093.
    PubMed     Abstract available


  369. CINTHI M, Coccitto SN, Fioriti S, Morroni G, et al
    Occurrence of a plasmid co-carrying cfr(D) and poxtA2 linezolid resistance genes in Enterococcus faecalis and Enterococcus casseliflavus from porcine manure, Italy.
    J Antimicrob Chemother. 2021 Dec 15. pii: 6463073. doi: 10.1093.
    PubMed     Abstract available


  370. SHANG Y, Lv P, Su D, Li Y, et al
    Evolutionary conservative analysis revealed novel functional sites in the efflux pump NorA of Staphylococcus aureus.
    J Antimicrob Chemother. 2021 Dec 15. pii: 6463078. doi: 10.1093.
    PubMed     Abstract available


  371. PIRES J, Huisman JS, Bonhoeffer S, Van Boeckel TP, et al
    Increase in antimicrobial resistance in Escherichia coli in food animals between 1980 and 2018 assessed using genomes from public databases.
    J Antimicrob Chemother. 2021 Dec 11. pii: 6459599. doi: 10.1093.
    PubMed     Abstract available


  372. HOLLAND M, Bjanes E, Nizet V, Dillon N, et al
    Bicarbonate modulates delafloxacin activity against MDR Staphylococcus aureus and Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2021 Dec 10. pii: 6459101. doi: 10.1093.
    PubMed     Abstract available


  373. CEBALLOS-GARZON A, Monteoliva L, Gil C, Alvarez-Moreno C, et al
    Genotypic, proteomic, and phenotypic approaches to decipher the response to caspofungin and calcineurin inhibitors in clinical isolates of echinocandin-resistant Candida glabrata.
    J Antimicrob Chemother. 2021 Dec 10. pii: 6459103. doi: 10.1093.
    PubMed     Abstract available


  374. DIAZ-DIAZ S, Recacha E, Garcia-Duque A, Docobo-Perez F, et al
    Effect of RecA inactivation and detoxification systems on the evolution of ciprofloxacin resistance in Escherichia coli.
    J Antimicrob Chemother. 2021 Dec 8. pii: 6456190. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  375. CHEUNG CY, McNeil MB, Cook GM
    Utilization of CRISPR interference to investigate the contribution of genes to pathogenesis in a macrophage model of Mycobacterium tuberculosis infection.
    J Antimicrob Chemother. 2021 Nov 28. pii: 6445137. doi: 10.1093.
    PubMed     Abstract available


  376. COCCITTO SN, Cinthi M, Fioriti S, Morroni G, et al
    Linezolid-resistant Enterococcus gallinarum isolate of swine origin carrying cfr, optrA and poxtA genes.
    J Antimicrob Chemother. 2021 Nov 23. pii: 6433473. doi: 10.1093.
    PubMed     Abstract available


  377. WILCOX MH, Dryden M
    Update on the epidemiology of healthcare-acquired bacterial infections: focus on complicated skin and skin structure infections.
    J Antimicrob Chemother. 2021;76.
    PubMed     Abstract available


  378. MARR I, Swe K, Henderson A, Lacey JA, et al
    Cefazolin susceptibility of coagulase-negative staphylococci (CoNS) causing late-onset neonatal bacteraemia.
    J Antimicrob Chemother. 2021 Nov 13. pii: 6427455. doi: 10.1093.
    PubMed     Abstract available


  379. MYLONA E, Voong Vinh P, Qureshi S, Karkey A, et al
    Tebipenem as an oral alternative for the treatment of typhoid caused by XDR Salmonella Typhi.
    J Antimicrob Chemother. 2021;76:3197-3200.
    PubMed     Abstract available


  380. AL-MIR H, Osman M, Drapeau A, Hamze M, et al
    Spread of ESC-, carbapenem- and colistin-resistant Escherichia coli clones and plasmids within and between food workers in Lebanon.
    J Antimicrob Chemother. 2021;76:3135-3143.
    PubMed     Abstract available


  381. ZHANG S, Liu P, Wang Y, Shen Z, et al
    Multiresistance gene cfr(C) in Clostridium perfringens of cattle origin from China.
    J Antimicrob Chemother. 2021;76:3310-3312.
    PubMed    


  382. BOOSTROM I, Bala Y, Vasic JM, Gluvakov J, et al
    Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial.
    J Antimicrob Chemother. 2021;76:3175-3182.
    PubMed     Abstract available


  383. LO FWY, Kong FYS, Hocking JS
    Treatment efficacy for rectal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials.
    J Antimicrob Chemother. 2021;76:3111-3124.
    PubMed     Abstract available


  384. SHASKOLSKIY B, Kandinov I, Kravtsov D, Filippova M, et al
    Prediction of ceftriaxone MIC in Neisseria gonorrhoeae using DNA microarray technology and regression analysis.
    J Antimicrob Chemother. 2021;76:3151-3158.
    PubMed     Abstract available


  385. HEARD F, Sehgal A
    Vancomycin in adult prescribing: is it time to move on from trough-based dosing in the UK?
    J Antimicrob Chemother. 2021;76:3071-3072.
    PubMed     Abstract available


  386. RAUWOLF KK, Hoertnagl C, Lass-Floerl C, Groll AH, et al
    Interaction in vitro of pulmonary surfactant with antifungal agents used for treatment and prevention of invasive aspergillosis.
    J Antimicrob Chemother. 2021 Nov 11. pii: 6425642. doi: 10.1093.
    PubMed     Abstract available


  387. EGAN SA, Kavanagh NL, Shore AC, Mollerup S, et al
    Genomic analysis of 600 vancomycin-resistant Enterococcus faecium reveals a high prevalence of ST80 and spread of similar vanA regions via IS1216E and plasmid transfer in diverse genetic lineages in Ireland.
    J Antimicrob Chemother. 2021 Nov 8. pii: 6423109. doi: 10.1093.
    PubMed     Abstract available


  388. TANG N, Hu J, Zhao Y, Song Y, et al
    In vivo evolution of carbapenem resistance in hypervirulent Klebsiella pneumoniae in a patient undergoing long-term treatment.
    J Antimicrob Chemother. 2021 Nov 2. pii: 6415960. doi: 10.1093.
    PubMed    


    October 2021
  389. PRATAMA R, Beukers AG, McIver CJ, Keighley CL, et al
    A vanA vancomycin-resistant Enterococcus faecium ST80 outbreak resulting from a single importation event.
    J Antimicrob Chemother. 2021 Oct 29. pii: 6414308. doi: 10.1093.
    PubMed     Abstract available


  390. JEN FE, El-Deeb IM, Zalucki YM, Edwards JL, et al
    A drug candidate for Alzheimer's and Huntington's disease, PBT2, can be repurposed to render Neisseria gonorrhoeae susceptible to natural cationic antimicrobial peptides.
    J Antimicrob Chemother. 2021;76:2850-2853.
    PubMed     Abstract available


  391. BORTOLAIA V, Ronco T, Romascu L, Nicorescu I, et al
    Co-localization of carbapenem (blaOXA-162) and colistin (mcr-1) resistance genes on a transferable IncHI2 plasmid in Escherichia coli of chicken origin.
    J Antimicrob Chemother. 2021;76:3063-3065.
    PubMed    


  392. ADACHI F, Sekizuka T, Yamato M, Fukuoka K, et al
    Characterization of FRI carbapenemase-producing Enterobacter spp. isolated from a hospital and the environment in Osaka, Japan.
    J Antimicrob Chemother. 2021;76:3061-3062.
    PubMed    


  393. GOLDEN AR, Karlowsky JA, Walkty A, Baxter MR, et al
    Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007-18.
    J Antimicrob Chemother. 2021;76:2825-2832.
    PubMed     Abstract available


  394. KARLOWSKY JA, Walkty A, Golden AR, Baxter MR, et al
    ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007-18.
    J Antimicrob Chemother. 2021;76:2815-2824.
    PubMed     Abstract available


  395. ZAHR N, Urien S, Aubry A, Chauvin C, et al
    Ciprofloxacin population pharmacokinetics during long-term treatment of osteoarticular infections.
    J Antimicrob Chemother. 2021;76:2906-2913.
    PubMed     Abstract available


  396. RING K, Shiva F
    Comment on: Clinical and serological outcomes in patients treated with oral doxycycline for early neurosyphilis.
    J Antimicrob Chemother. 2021;76:3067-3068.
    PubMed    


  397. ADAMSON PC, Lin EY, Ha SM, Klausner JD, et al
    Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance.
    J Antimicrob Chemother. 2021;76:2847-2849.
    PubMed     Abstract available


  398. GOLDSTEIN E
    Rise in the prevalence of resistance to extended-spectrum cephalosporins in the USA, nursing homes and antibiotic prescribing in outpatient and inpatient settings.
    J Antimicrob Chemother. 2021;76:2745-2747.
    PubMed     Abstract available


  399. CHARRET L, Bart G, Hoppe E, Dernis E, et al
    Clinical characteristics and management of olecranon and prepatellar septic bursitis in a multicentre study.
    J Antimicrob Chemother. 2021;76:3029-3032.
    PubMed     Abstract available


    September 2021
  400. ENGBERG J, Vejrum LK, Madsen TV, Nielsen XC, et al
    Verification of analytical bacterial spectrum of QIAstat-Dx(R) GI V2 and Novodiag(R) Bacterial GE+ V2-0 diagnostic panels.
    J Antimicrob Chemother. 2021;76.
    PubMed     Abstract available


  401. ZHANG X, Wang L, Li D, Wang C, et al
    Characterization of the novel plasmid-encoded MBL gene blaAFM-1, integrated into a blaIMP-45-bearing transposon Tn6485e in a carbapenem-resistant Pseudomonas aeruginosa clinical isolate.
    J Antimicrob Chemother. 2021 Sep 17. pii: 6371932. doi: 10.1093.
    PubMed     Abstract available


  402. DIEZ-AGUILAR M, Ekkelenkamp M, Morosini MI, Huertas N, et al
    Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates.
    J Antimicrob Chemother. 2021;76:2578-2585.
    PubMed     Abstract available


  403. SASS G, Larwood DJ, Martinez M, Shrestha P, et al
    Efficacy of nikkomycin Z in murine CNS coccidioidomycosis: modelling sustained-release dosing.
    J Antimicrob Chemother. 2021;76:2629-2635.
    PubMed     Abstract available


  404. GEBREMARIAM T, Gu Y, Singh S, Kitt TM, et al
    Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis.
    J Antimicrob Chemother. 2021;76:2636-2639.
    PubMed     Abstract available


  405. DARAGON B, Fournier D, Plesiat P, Jeannot K, et al
    Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2021;76:2586-2592.
    PubMed     Abstract available


  406. PALACE SG, Fryling KE, Li Y, Wentworth AJ, et al
    Identification of bile acid and fatty acid species as candidate rapidly bactericidal agents for topical treatment of gonorrhoea.
    J Antimicrob Chemother. 2021;76:2569-2577.
    PubMed     Abstract available


  407. ROYER G, Poirel L, La Combe B, Clermont O, et al
    Lack of association between colistin resistance and chlorhexidine reduced susceptibility in clinical isolates of Escherichia coli.
    J Antimicrob Chemother. 2021;76:2736-2737.
    PubMed    


  408. MAMA OM, Aspiroz C, Lozano C, Ruiz-Ripa L, et al
    Penicillin susceptibility among invasive MSSA infections: a multicentre study in 16 Spanish hospitals.
    J Antimicrob Chemother. 2021;76:2519-2527.
    PubMed     Abstract available


  409. RAISANEN K, Sarvikivi E, Arifulla D, Pietikainen R, et al
    Three clusters of carbapenemase-producing Citrobacter freundii in Finland, 2016-20.
    J Antimicrob Chemother. 2021;76:2697-2701.
    PubMed     Abstract available


  410. BIEDRZYCKA M, Urbanowicz P, Guzek A, Brisse S, et al
    Dissemination of Klebsiella pneumoniae ST147 NDM-1 in Poland, 2015-19.
    J Antimicrob Chemother. 2021;76:2538-2545.
    PubMed     Abstract available


  411. ABE R, Oyama F, Akeda Y, Nozaki M, et al
    Hospital-wide outbreaks of carbapenem-resistant Enterobacteriaceae horizontally spread through a clonal plasmid harbouring blaIMP-1 in children's hospitals in Japan.
    J Antimicrob Chemother. 2021 Sep 3. pii: 6363635. doi: 10.1093.
    PubMed    


    August 2021
  412. MOUNSEY O, Schubert H, Findlay J, Morley K, et al
    Limited phylogenetic overlap between fluoroquinolone-resistant Escherichia coli isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region.
    J Antimicrob Chemother. 2021 Aug 27. pii: 6358704. doi: 10.1093.
    PubMed     Abstract available


  413. URBANOWICZ P, Izdebski R, Baraniak A, Zabicka D, et al
    Molecular and genomic epidemiology of VIM/IMP-like metallo-beta-lactamase-producing Pseudomonas aeruginosa genotypes in Poland.
    J Antimicrob Chemother. 2021;76:2273-2284.
    PubMed     Abstract available


  414. TYDEMAN F, Craine N, Kavanagh K, Adams H, et al
    Incidence of Clostridioides difficile infection (CDI) related to antibiotic prescribing by GP surgeries in Wales.
    J Antimicrob Chemother. 2021;76:2437-2445.
    PubMed     Abstract available


  415. MUNTEAN MM, Muntean AA, Guerin F, Cattoir V, et al
    Optimization of the rapid carbapenem inactivation method for use with AmpC hyperproducers.
    J Antimicrob Chemother. 2021;76:2294-2301.
    PubMed     Abstract available


  416. SIX A, Mosbahi K, Barge M, Kleanthous C, et al
    Pyocin efficacy in a murine model of Pseudomonas aeruginosa sepsis.
    J Antimicrob Chemother. 2021;76:2317-2324.
    PubMed     Abstract available


  417. LI R, Peng K, Xiao X, Wang Y, et al
    Characterization of novel ISAba1-bounded tet(X15)-bearing composite transposon Tn6866 in Acinetobacter variabilis.
    J Antimicrob Chemother. 2021;76:2481-2483.
    PubMed    


  418. VADLAMUDI NK, Saatchi A, Patrick DM, Rose C, et al
    Impact of the 13-valent pneumococcal conjugate vaccine on acute otitis media and acute sinusitis epidemiology in British Columbia, Canada.
    J Antimicrob Chemother. 2021;76:2419-2427.
    PubMed     Abstract available


  419. MACVANE SH, Bhalodi AA, Dare RK, Rosenbaum ER, et al
    Improving outcomes and antibiotic stewardship (IOAS) for patients with Gram-positive bloodstream infections through use of rapid testing: a quasi-experimental multicentre study of the Accelerate PhenoTest BC Kit.
    J Antimicrob Chemother. 2021;76:2453-2463.
    PubMed     Abstract available


  420. COCCITTO SN, Fioriti S, Cinthi M, Morroni G, et al
    Detection of phenicol-oxazolidinone resistance gene optrA in Aerococcus viridans from bovine faeces, Italy.
    J Antimicrob Chemother. 2021;76:2479-2481.
    PubMed    


    July 2021
  421. LUCENA NEMIROSKY J, Espelt R, Lopez Grado E, Sobrino J, et al
    Macrolide resistance in Mycoplasma genitalium in Catalonia, Spain: a 1 year prospective study.
    J Antimicrob Chemother. 2021 Jul 19. pii: 6323546. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bacterial Infections and Mycoses is free of charge.